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Resumo 
 Atualmente relacionam-se os níveis elevados de homocisteína (Hcys) com uma maior 
incidência no desenvolvimento de doenças cardiovasculares (CVDs), em especial a 
aterosclerose. De igual forma, associa-se o baixo nível das vitaminas B6, B9 e B12 a uma 
instabilidade no ciclo da metionina com excessiva produção de Hcys. Desta forma, as ciências 
biomédicas têm procurado encontrar uma metodologia analítica para a quantificação em 
ambiente clínico e hospitalar destes compostos, que seja mais barata, rápida, precisa e exata, 
face às já existentes. Este constituiu assim o objetivo deste estudo, tendo-se utilizado um 
procedimento que integrava a microextração em seringa empacotada (MEPS) controlada 
digitalmente (eVol®) como técnica extrativa e um sistema de cromatografia líquida de ultra 
eficiência (UPLC) acoplado a um detetor de fotodiodos (PDA) como forma de identificar e 
quantificar a Hcys e as vitaminas B6, B9 e B12. 
 No seguimento do trabalho experimental, não foi possível combinar a Hcys e as 
vitaminas num mesmo procedimento analítico, tendo-se procedido à otimização de dois 
procedimentos diferentes, um para Hcys e outro para as três vitaminas, que apenas divergiam na 
constituição do gradiente da fase móvel e do volume injetado. Verificou-se que a MEPS não 
trazia benefícios para a quantificação da Hcys no plasma, procedendo-se assim à validação de 
um método alternativo que usa a injeção direta de plasma previamente tratado (reduzido e 
precipitado). Este mesmo método foi avaliado em termos de seletividade, linearidade, limite de 
deteção (LOD), limite de quantificação (LOQ), efeito matriz e precisão (intra e inter-dia) e 
aplicado na determinação da Hcys num grupo constituído por pacientes com doença 
cardiovascular. Obtiveram-se bons resultados em termos de seletividade, de linearidade (R
2
> 
0,9968), de LOD (0.07 μmol/L) e LOQ (0.21 μmol/L). A precisão intra-dia (1.23 – 3.32 %), 
precisão inter-dia (5.43 – 6.99 %) e a taxa de recuperação (82.5 a 93.1%) deste método foram 
satisfatórios. Obteve-se, porém, um efeito matriz superior a 120%, bastante mais elevado que o 
desejável. Quanto à aplicação prática desta metodologia, foi possível determinar a quantidade de 
Hcys nos indivíduos-alvo deste estudo. Em relação à metodologia desenvolvida para as 
vitaminas, apesar da otimização da técnica extrativa e das condições cromatográficas, 
constatou-se que que os níveis normalmente presentes no plasma estão muito abaixo da 
sensibilidade do aparelho, pelo que será necessário otimizar ainda mais o procedimento 
experimental.    
 Como conclusão, parte dos objetivos deste estudo foram concretizados, tendo sido 
possível validar um método rápido, simples e barato para quantificação da Hcys em plasma.   
 Palavras-chave: Homocisteína (Hcys); Aterosclerose; Doenças cardiovasculares; 
Cromatografia líquida de alta eficiência (UPLC); Validação;  
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Abstract  
A large number of evidences correlate elevated levels of homocysteine (Hcys) with a 
higher cardiovascular diseases (CVDs) risk, especially, atherosclerosis. Similarly, abnormal low 
levels of the vitamins B6, B9 and B12 are associated to an instability in the methionine cycle with 
an over production of Hcys. Thus, biomedical sciences are looking forward for a cheaper, faster, 
precise and accurate analytical methodology to quantify these compounds in a suitable format 
for the clinical environment. Therefore the objective of this study was the development of a 
simple, inexpensive and appropriate methodology to use at the clinical level. To achieve this 
goal, a procedure integrating a digitally controlled (eVol
®
) microextraction by packed sorbent 
(MEPS) and an ultra performance liquid chromatography (UPLC) coupled to a photodiode array 
detector (PDA) was developed to identify and quantify Hcys vitamins B6, B9 and B12.  
Although different conditions were assayed, we were not able to combine Hcys with the 
vitamins in the same analytical procedure, and so we proceeded to the optimization of two 
methods differing only in the composition of the gradient of the mobile phase and the injected 
volume. It was found that MEPS did not bring any benefit to the quantification of the Hcys in 
the plasma. Therefore, we developed and validate an alternative method that uses the direct 
injection of treated plasma (reduced and precipitated). This same method was evaluated in terms 
of selectivity, linearity, limit of detection (LOD), limit of quantification (LOQ), matrix effect 
and precision (intra-and inter-day) and applied to the determination of Hcys in a group 
composed by patients presenting augmented CVD risk. Good results in terms of selectivity and 
linearity (R
2
> 0.9968) were obtained, being the values of LOD and LOQ 0.007 and 0.21 mol / 
L, respectively. The intra-day precision (1.23-3.32%), inter-day precision (5.43-6.99%) and the 
recovery rate (82.5 to 93.1%) of this method were satisfactory. The matrix effect (>120%) was, 
however, higher than we were waiting for. Using this methodology it was possible to determine 
the amount of Hcys in real plasma samples from individuals presenting augmented CVD risk. 
Regarding the methodology developed for vitamins, despite the optimization of the extraction 
technique and the chromatographic conditions, it was found that the levels usually present in 
plasma are far below the sensitivity we obtained. Therefore, further optimizations of the 
methodology developed are needed. 
As conclusion, part of the objectives of this study was achieved with the development of a 
quick, simple and cheaper method for the quantification of Hcys. 
Keywords: homocysteine (Hcys), cardiovascular diseases (CVDs), atherosclerosis, ultra 
performance liquid chromatography (UPLC); validation; 
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Aims 
Given the crucial role of Hcys and vitamin B-cofactors for the onset of several diseases such 
as atherosclerosis, as well as the great interest in the development of a simple, cheaper and 
reliable analytical methodology for the quantification of these compounds, suitable for the 
clinical quantification, the aim of this study was the development of a method to quantify the 
total Hcys and vitamin B-cofactors  through the use of Microextraction by packed sorbent 
(MEPS) followed Ultra Performance Liquid Chromatography (UPLC) coupled  with 
Photodiode Array (PDA) detector.  
MEPS was chosen as the extraction technique according to the quality of extraction it 
provides at a relatively cheap price. The use of UPLC coupled with PDA detector was also 
selected taking in account the price and the quality of the quantification when compared to 
others chromatographic assays such as Liquid Chromatography/Mass spectrometry (LC/MS) 
and different immunoassays possibilities, which allows only total Hcys quantification. 
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Chapter I: Bibliographic revision  
Throughout this chapter some topics considered essential for the understanding of the 
purpose of this study will be discussed. 
 
1.1. Cardiovascular diseases 
The Cardiovascular diseases (CVDs) include a group of disorders of the heart and blood 
vessels that actually represent the leading cause of death by illness worldwide. They include 
coronary heart disease (CHD), ischemic strokes, rheumatic heart disease (RHD), 
cardiomyopathy, and other heart diseases such as congenital heart disease, deep vein thrombosis 
or pulmonary embolism [1-3]. Although most CVDs in the world are due atherosclerosis (CHD 
and ischemic strokes), other CVDs due to infection (RHD, Chagas’ heart disease, 
cardiomyopathy from human immunodeficiency virus (HIV)  infection, cerebrovascular 
complications of malaria and among others)  remain common in many regions of the developing 
world [1].  
According with Word Heath Organization (WHO) of a total 57 million deaths occurring in 
2008, 36 million (63%) were due Non-communicable Diseases (NCDs), mainly cardiovascular 
disease, diabetes, cancers and chronic respiratory diseases. Of these deaths, an estimated of 17 
million deaths were due CVDs (48% of NCDs), namely 7.3 million for CHD and 6.2 million for 
ischemic stroke. Furthermore, over 80% of these CVD deaths took place in low and middle-
income countries and occurred almost equally in men and women [2, 3]. 
By population growth and increase of the life expectancy, it is envisaged an increasing 
number and proportions of older people, verifying the emerging of a population more ageing as 
a significant trend in many parts of the world.  So as population’s age increase, annual NCD 
deaths are projected to rise substantially to 52 million in 2030, and concerning to annual CVD 
mortality, it is expected an increase by 6 million to a total value of 23 million in 2030 [3, 4].  
Word Heart Federation considers that the major part of CVDs is caused by risk factors that 
can be controlled, treated or modified, such as high blood pressure (hypertension), tobacco use, 
raised blood glucose (diabetes), physical inactivity, unhealthy diet, raised blood choles-
terol/lipids, overweight and obesity [5]. However, there are also some major CVD risk factors 
that cannot be controlled such as the age, gender and familiar history. Regarding to the 
attributable of deaths by risk factors worldwide, the leading CVDs risk factor is hypertension 
(13 per cent of global), followed by tobacco use (9 per cent), diabetes (6 per cent), physical 
inactivity (6 per cent) and overweight and obesity (5 per cent) [3, 5]  
Figure 1 - Evolution of atherosclerosis. Image obtained from Rader et al [6]. 
1.2. Atherosclerosis 
Atherosclerosis is a complex pathological process in the walls of blood vessels that 
develops over many years, being the responsible for a large proportion of CVDs and the most 
common cause of death in Western societies [3].  It is a result of blood vessels ageing, with 
initial lesion developing before age 30 (Figure 1) [6].  
Atherosclerosis is recognized as a local inflammation originated by the formation of 
subintimal plaques in the innermost layer of an artery (intima). This layer is, composed by 
endothelial cells, elastic connective tissue and percytes, and the plaques formed can reduce or 
obstruct blood flow through the vessel [7, 8]. The process continues with the accumulation of 
plasma low-density-lipoproteins (LDL) in the walls of medium and large arteries, such as the 
coronaries, carotids and the aorta [9]. An atherosclerotic symptomatic event manifests itself 
clinically as myocardial infarction and stroke and their respective precursor disorders, angina 
pectoris and transient ischaemic attacks of the brain [10].  
 
 
WHO defines three kinds of risk factors at the rear of the atherosclerosis development [3]:
  
 
 Behaviour risk factors:  tobacco use; physical inactivity; unhealthy diet (rich in salt, fat 
and calories); harmful use of alcohol. 
 Metabolic risk factors: raised blood pressure (hypertension); raised blood sugar (diabe-
tes); raised blood lipids (hypercholesterolemia); overweight and obesity. 
 Other risk factors: poverty and low education status; advancing age; gender; inherit ge-
netic disposition; psychological factors (stress, depression); and excess of homocysteine.
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Among these risk factors, elevated levels of serum cholesterol are probably the unique 
factor capable to being sufficient to drive the development of atherosclerosis, even in the 
absence of other known risk factor. However, the presence of others risk factors together with 
hypercholesterolemia contribute for a faster development of the disease, once the main 
pathophysiological mechanism in atherosclerosis is an endothelium dysfunction that, despite 
hypercholesterolemia, can be developed by some of these other factors and so facilitate an 
increased entry and accumulation of LDL into artery walls [10, 11]. 
  Atherosclerotics lesions (atheromata) are asymmetric focal thickenings of cells, 
connective-elements, lipids and debris. Blood-borne inflammatory agents (microbes, 
autoantigens and other molecules) and immune cells constitute an important part of an atheroma 
(one single atherosclerotic lesion), while the remainder are vascular endothelial and smooth 
muscle cells. The atheroma is preceded by a fatty streak, an accumulation of lipid-laden cells 
(foam cells) beneath the endothelium, wherein the most of these cells are macrophages, together 
with T cells [9]. 
Once an atheromatous process prevents blood flow through the artery it was believed that 
an ischemia and infarction’s event occurs. However, some recent angiographic studies proved 
that acute myocardial infarction and stroke do not occur generally by stenosis or progressive 
luminal narrowing from the continued growth of smooth muscle cells in the plaque, but 
essentially, by the activation of the plaque and the formation of an occluding thrombus on the 
surface of these vessels [12].  
In this context, atherosclerosis is regarded as an event in chain, which includes a set of key 
steps that begins with: 1) an endothelial dysfunction: 2) the retention and oxidation of LDL in 
the arterial wall; 3) an immune response and formation of a fatty streak lesion and 4) the 
subsequent rupture of the plaque and the formation of an occlusive thrombus [6, 9-11]. Each 
step will be explained in more detail in the following subtopics. 
1.2.1. Endothelial dysfunction  
The endothelium is the major regulator of the vascular wall homeostasis. Endothelium 
maintains the balance between vasodilation and vasoconstriction; regulates vascular 
permeability to plasma constituents, platelet and leukocyte adhesion and aggregation; inhibits 
and stimulates smooth muscle cell proliferation and migration, thrombogenesis, fibrinolysis; 
and maintains low levels of oxidative stress by releasing mediators such as nitric oxide (NO), 
prostacyclin (PGI2) and controlling endothelin (ET-1) and local angiotensin-II activity. 
Nevertheless, this balanced endothelial regulation can be altered by a number of conditions, 
causing damage to an arterial wall [13, 14].
 
 
In response to a variety of noxious stimuli, the endothelium undergoes phenotypical 
modulation to a non-adaptive state (endothelial dysfunction), which is characterized by the loss 
or deregulation of the homeostatic mechanisms (balance between vasoconstriction and 
vasodilation mediators) that operate in healthy endothelial cells. This pathophysiological 
condition (Figure 2) is associated with the increased of the endothelial permeability, an 
increased expression of adhesion molecules, platelet aggregation, the synthesis of pro-
inflammatory and pro-thrombotic factors, the increased of the oxidative stress, and the abnormal 
modulation of vascular tone by decreased production or activity of NO,  in which all of these 
changes  may lead to functional manifestations that includes impaired endothelium dependent 
vasodilation [13-15].  
According with the Figure 2, the CVD risk factors promote an increased production of 
Reactive Oxygen Species (ROS), which in turn, deregulate the endothelium homeostasis by a 
decreased production of NO. This is caused by the inactivation of the enzyme endothelial NO 
synthase (eNOS) and by the formation of ET-1, thromboxane A2 (TxA2) and others contractive 
molecules such as angiotensin-1 and angiotensin-2. Once produced in significant amount, these 
molecules trigger an inflammatory response that involves several processes: 
- Fibrinolysis is inhibited by the action of plasminogen activator inhibitor (PAI-1);  
- Platelet aggregation occurs by the action of TxA2 and von Willebrand factor (vWF) or 
diminished action of NO and PGL2, which inhibit this process;  
- Leukocyte and platelets adhesiveness and migration occur through the action of some 
adhesion molecules: E-selectin, P-selectin, Intercellular adhesion molecule-1 (ICAM-1), 
vascular cell adhesion molecule-1 (VCAM-1) and platelet-endothelial cell adhesion molecule-1 
(PCAM-1);  
- Coagulation begins with the endothelium production of tissue factor (TF), inhibition of 
thrombomodulin (TM) production, and a diminished presence of glycosaminoglycans (GAG) 
[14-19]. 
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Figure 2 – Endothelium dysfunction mechanism. Legend: ROS| Reactive Oxygen Species; NO| Nitric Oxide; eNOS| Enzyme NO 
synthase; ET-1| Endothelin-1; TxA2| thromboxane A2;  PAI-1| Plasminogen activator inhibitor; vWF| Von Willebrand factor; PGL2| 
Prostacyclin; ICAM-1| Intercellular adhesion molecule-1; VCAM-1| Vascular cell adhesion molecule-1; PCAM-1| Platelet-endothelial 
cell adhesion molecule-1; TF| Tissue factor; TM| Thrombomodulin; GAG| Glycosaminoglycans. Image adapted from [14-19].  
 
 
  
 
 
 
 
 
 
 
Current evidence suggests that endothelial dysfunction occurs early in the process of the 
atherogenesis and contributes to the formation, progression, and complications of atheroscle-
rotic plaque. It is so considered an early marker for atherosclerosis, preceding even 
angiographic or ultrasonic evidence of an atherosclerotic plaque.  Several studies have shown 
that patients with CVDs risk factors without any clinical signs of atherosclerosis are affected by 
endothelial dysfunction, through their impaired response to endothelial vasodilators such as 
acetylcholine and bradykini, suggesting that endothelial dysfunction is a common mechanism 
between atherosclerotic risk factors and the development of atherosclerosis, and the risk factor 
score (the total number of risk factor in a given patient) as potent independent predictor of the 
endothelial dysfunction. Furthermore, some studies have shown that the endothelial dysfunction 
is an independent predictor of future CVDs event in patients with atherosclerotic risk factors, or 
stable ischemic heart disease, or acute coronary syndromes. Therefore, endothelial dysfunction 
seems to be a systemic vascular process that not only mediates the development of an 
atherosclerotic plaque, but may also modulate its clinical course [13].  
1.2.2.  LDL retention and oxidation into artery walls and activation of the  immune cells 
1.2.2.1. Lipoprotein metabolism 
The most important plasma lipids are cholesterol and triglyceride (TG). Cholesterol has 
various roles: it is a component of cell membranes; the precursor for the steroid hormones, 
vitamin D, oxysterols and bile acids; and it is required for the activation of neuronal signalling 
molecules. Only a small amount of the circulating cholesterol is originated from the diet and 
around 80% is derived from endogenous synthesis, which 3-hydroxy-3-methylglutaryl 
coenzyme A reductase (HMGCR) catalyses the rate-limiting step. Most cholesterol in the 
circulation is esterified, with free cholesterol constituting a minor fraction. TG is a key energy 
source that is made up of free fatty acids (FFAs) that are ester-linked to a glycerol backbone. It 
is synthesized in intestinal and liver cells and is then transported through the plasma and, after 
lipolysis, at the endothelial surface, where delivers FFAs to peripheral cells for β-oxidation or 
storage. Owing the insolubility of cholesterol and TG in plasma, they are transported in 
steroidal macromolecules called lipoproteins, which have a hydrophobic core containing 
phospholipid, fat-soluble antioxidants and vitamins, cholesteryl ester, and a hydrophilic coat 
that contains free cholesterol, phospholipid and apolipoprotein molecules. Lipoproteins are 
specifically targeted to cells by distinct apolipoproteins (Apo) on their surface, which enables 
tissue recognize and take up the lipoprotein particle via specific cell receptors. The main TG-
carrying lipoproteins are chylomicron (CM) and very low-density lipoprotein (VLDL). The 
main cholesterol-carrying lipoproteins are LDL and high-density lipoprotein (HDL). 
Lipoproteins are distinguished from each other by size, density, electrophoretic mobility, 
composition and function (Figure 3) [20-22].  
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Figure 3 - General Structure and physical proprieties of human plasma lipoproteins. Adapted from Wasan et al [22]. 
 
 
 
 
 
 
 
 
 
 
Lipoprotein metabolism is a complex network of assembly, secretion, processing and 
catabolism that involves the transport of lipids, particularly cholesterol and TG in the blood 
(Figure 4). Briefly, the intestine absorbs dietary fat via free fatty acid (FFA) transporters and 
packages it into chylomicrons, which are transported to peripheral tissues through the blood. In 
the capillaries of the muscle and adipose tissue, chylomicrons bind to 
glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHPB1) and interact with the 
enzyme lipoprotein lipase (LPL), which it is in turn held by the proteoglycans on the 
endothelium surface. The enzyme then breaks chylomicrons and FFA enters these tissues. The 
chylomicron remnants are subsequently taken by the liver.  In liver, cholesterol is recycled or 
synthesized again with HMGCR. Some part of it is esterified with FFAs via cholesterol-
acyltransferase to form colesteryl ester, which is then stored together with TG inside the nascent 
VLDL that contains an apolipoprotein apoB100 in its structure. The nascent VLDL leaves the 
liver to the periphery.  In its course to target-tissues, nascent VLDL becomes a mature VLDL, 
after receive from HDL the apolipoproteins apoC2 and apoE. Already in the capillaries of the 
peripherals tissues, the apolipoproteins apoB100 and apoE bind to the VLDL receptors at the 
endothelial cell, and apoC2 activates the LPL that is still stimulated by insulin, to hydrolyze the 
triacylglicerol inside de VLDL, producing fatty acids and glycerol. This procedure of deliver 
leads to the formation of the intermediate-density-lipoprotein (IDL) from VLDL, which is very 
rich in cholesterol. After, the exclusion of the apoE from IDL by hepatic lipases, LDL is 
produced, which, in turn, leaves the circulatory system and delivers the cholesterol toward the 
binding of apoB100 with LDL receptors in liver as well as endothelium cells from peripheral 
Figure 4 - lipoprotein metabolism. The details regarding of the chylomicrons binding with endothelial cells to release fatty acids, the  
maturation of the nascent VLDL as well as the modification of the IDL to LDL and the formation of HDL are not shown in this illustration.  
Legend: C| Cholesterol; NPC1L1| Niemann-Pick C1-like; ABCG5/G8| Heterodimeric ATP-binding cassette transporter G5/G8; FA| 
Fatty acid; MTTP| Microsomal TG-transfer protein; CM| Chylomicron; B48|  Apolipoprotein B48; C2| Apolipoprotein C2; A5| 
Apolipoprotein A5; C3| Apolipoprotein C3; LPL| Lipoprotein lipase; DGAT| Acyl-CoA:diacylglycerol acyltransferase; ATGL| Adipose 
triglyceride lipase; HSL| Hormone sensitive lipase; CMR| Chylomicron remnants; LRP1| LDL Receptor –related protein -1; HMGCR| 3-
Hydroxy-3-methylglutaryl coenzyme A reductase; B100| Apolipoprotein B100; VLDL| Very-low-density-lipoprotein; IDL| Intermediary-
density-lipoprotein; HL| Hepatic lipase; LDL| Low-density-lipoprotein; LDLR| LDL receptor; AP| Adaptor protein; PCSK9| Proprotein 
convertase subtilisin/kexin type 9; X| Degradation; HDL| High-density-lipoprotein;  A1| Apolipoprotein A1; ABCA1| ATP-binding 
cassette A1; ABGC| ATP-binding cassette transporter G1; LCAT| Lecithincholesterol acyltransferase; CETP| Cholesterol ester transfer 
protein; LIPG| endothelial lipase; SRB1| Scavenger receptor class B type I. Image obtained from Rader et al [6]. 
 
tissues. By the contrast, HDL mediates the reverse cholesterol transport. It is generated by the 
intestine and the liver through the secretion of lipid-free apoA-1. It promotes the cellular efflux 
of cholesterol from tissues through the interaction of apoA-1 with ATP-binding cassette A1 
(ABCA1), ATP-binding cassette transporter G1 (ABCG1) and Lecithincholesterol 
acyltransferase (LCAT), which esterifies cholesterol so it can be used in HDL cholesterol. And 
it leaves the circulatory system by the hepatocytes via scavenger receptor class B type I (SRB1), 
through the remodelling by cholesterol ester transfer protein and by endothelial lipase (LIPG) 
[6, 20-23]. 
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Figure 5 - Proteoglycans structure and interaction with LDL.  A| The most common types of proteoglycans in an arterial wall. B| 
The LDL – proteoglycan interaction. Clusters of positively charged amino acids on apolipoprotein B bind to negatively charged 
glycosaminoglycan (GAG) chains on proteoglycans. Image adapted from Fogelstrand et al [24].  
1.2.2.2. LDL and the beginning of an atherosclerotic lesion 
As discussed previously, atherosclerotic lesion develops from an increase accumulation of 
LDL particles at the connective tissue basement membrane that constitutes the intima layer, due 
an endothelium injury.  Since cardiovascular risk factors, especially hypercholesterolemia, can 
promote an endothelial dysfunction and a consequent increase of permeability, blood LDL 
molecules, as they are the smallest lipoproteins (18-25 nm), can easily infiltrate the endothelium 
of an artery and reach the subendothelial space in significantly amount. Once there, LDL can be 
trapped due an undesired bond between apoB100 with some proteoglycans that constitute the 
extracellular matrix (ECM) [24]. 
The first determinants steps for an atherosclerotic event are the rate of LDL entry and exit 
from the intima layer to the plasma, through the endothelium. Once in the intima, the particles 
may continue into the muscular media and may be processed by cells or may be sequestered by 
interactions with ECM. However, in normal endothelium, neither apoB100 lipoproteins nor 
their lipids accumulate with time in the normal intima. It seems that in normal conditions, most 
particles return to plasma from the fluid phase, and those that are associated with the matrix are 
taken by cells and degraded in situ [25].
  
The proteoglycans are all composed of a core protein and one or more covalently attached 
GAGs, which are linear polysaccharides consisting of repeating disaccharide units (heparin 
sulphate, chondroitin sulphate, dermatan sulphate and keratin sulphate). There are five types of 
proteoglycans: biglycan, decorin, perlecan, versican and syndecan-4. Proteoglycans are 
negatively charged due to the acidic sugar groups on the GAG polysaccharide backbone and the 
addition of negatively charged sulphate groups. ApoB100 binds to negatively charged GAG 
chains on proteoglycans (Figure 5). Chondroitin sulphate proteoglycans, such as versican, are 
the main structural proteoglycans of the ECM and are considered important atherogenic 
elements [24, 26].
 
 
 
 
 
 
 
 
Figure 6 – Pathways of free radical-mediated lipid peroxidation. Legend:  X.| Free radical specie; LH| Polyunsatured lipids. 
Image obtained from Niki et al [27]. 
Lipid oxidation induces disturbance of the fine structures, alteration of integrity, and 
permebility, and function loss of biomembranes, modifies LDL to pro-atherogenic and pro-
inflammatory forms, and generates potentially toxic (mutagenic and carciongenic) products 
[27]. The oxidation process followed of an activation of immune cells goes after the binding of 
the LDL with proteoglycans. LDL particles trapped in ECM are susceptible to undergo 
modification processes (oxidized LDL and aggregated LDL particles) when they interact with 
ECM components, because of the action of certain oxidants (lipoxygenases, myeloperoxidase, 
free radicals, etc.) and/or because of proteolytic enzymes (kinase, tryptase, metalloproteinases, 
thrombin, etc.) lipolytic enzymes (sphingomyelinase, phospholipase A2, phospholipase C, etc.) 
and hydrolytic enzymes (esterases), and then they trigger the expression of adhesion molecules 
and the secretion of chemokines by endothelial cells, which, together with the deposition of 
platelet-derived chemokine, drive intimal immune cell infiltration [24, 26, 28]. Lipid 
peroxidation on LDL molecules occurs, either by enzymatic processes or by free radical species, 
as a chain mechanism, which an initiator oxidize many molecules of lipids, changing their 
original form. The Figure 6 shows an example of lipid modification by free radicals [27] .  
 
 
 LDL undergoes various degrees of oxidation and such diversity of LDL oxidation provides 
different atherogenic effects to the vascular cells (Figure 7). Oxidative modifications of LDL 
can occur in the absence of changes or little changes in apoB100. Such modified LDL is called 
minimally oxidized LDL (mmLDL), which retains the affinity to the LDL receptor. It has a little 
negative charge, activates anti-apoptotic signalling, and induces inflammatory changes with 
increased chemokines and cytokines. On the other hand, the recruitment of inflammatory cells 
results in a huge variety of enhanced cytokines and the continued oxidation of LDL.  
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Figure 7 - Mechanism of LDL oxidation and atherogenic effects. Image obtained from Yoshida et al [29]. 
Consequently, LDL constituents are further oxidized and the LDL protein constituents are also 
modified, leading to a loss of recognition by the LDL receptor and a shift to recognition by 
scavenger receptors (oxidized LDL receptors), leading to the development of macrophage foam 
cells [29]. According with the Figure 7, LDL that enters in the artery may be oxidized by some 
the action of certain oxidants. Minimally oxidized LDL stimulates adhesion molecules and 
chemokines but has low affinity to macrophages scavenger receptors, and thus, can be recycled 
into blood circulation and can be detected as a serum oxidized LDL. Extensively oxidized LDL 
can be taken up by macrophages through the scavenger receptor, leading to the formation of 
foam cells. However, either extensively or minimally oxidized LDL enhance macrophages 
scavenger receptors with various modulations of cytokines [29]. 
 
 
1.2.3. Inflammatory response, formation of a fatty streak lesion and lesion 
progression 
A critical step for the development of atherosclerotic lesions is the infiltration of circulating 
leukocytes into the intravascular space (Figure 8). The recruitment of mononuclear cells 
(monocytes and T lymphocytes) as a specialized inflammatory response to modified LDL 
exposure characterizes the initiation phase of the formation of an atherosclerotic lesion. Specific 
adhesion molecules such as vWF, the selectins, and VCAM-1, expressed on the surface of the 
activated vascular endothelial cells, mediate the leukocyte adhesion. Once adhered, the 
mononuclear cells enter into the artery wall guided by the chemoattractant chemokines such as 
monocytes chemoattractant protein-1 (MCP-1). When circulating peripheral monocytes migrate 
from the vascular to the extravascular space, occurs a parallel process that involves the 
maturation of these cells to macrophages. This differentiation process provides the cells ready 
for active participation in the inflammatory and immune response, and it is in turn amplified, by 
macrophage colony stimulating factor (MCSF), by lipopolyssacharide (LPS) via receptor CD14 
in conjugation with toll-like receptor 4 (TLR4), by the heat stock protein (HSP-60) via CD14, 
and through platelet activating factor (PAF) and cytokines released from macrophages in an 
autocrine loop [30].  
According with the Figure 8, hemodynamics forces play a major role in the determination of 
the locals of the lesion predilection. These forces, aggravated by cardiovascular risk factors, 
increase the endothelial permeability and consequently the entrance of LDL into the intima. 
Consequently, LDL is retained as a result of the interaction with the matrix components and 
oxidized by the interaction with ROS and/or others oxidant agents. This process stimulates the 
endothelial cells to produce several molecules, such as MCSF and MCP-1, and express variety 
of cellular adhesion molecules including ICAM-1 and VCAM-1, which participate in the 
recruitment of monocytes into the vessel wall. Likewise, oxidized LDL decreases the 
bioavailability of NO. Activated monocytes and T cell express important adhesion molecules, 
including integrins (VLA4 and β2) and PCAM-1 that binds to the endothelial surface. Within 
the vessel wall, MCSF stimulates the proliferation and differentiation of macrophages, and 
together with tumour necrosis factor-α (TNF-α) and interferon-ϒ (INF-ϒ) promote the 
expression of several scavenger receptor (for instance CD36, CD38 and scavenger receptor A 
[SR-A]). Those scavenger receptors recognize the highly oxidized and aggregated LDL, formed 
by the action of the ROS and some enzymes lipase and myeloperoxidase (MPO). This fact 
allows the rapid uptake of LDL particles by macrophages leading to the formation of foam cells. 
Foam cells will die, forming a mass of extracellular lipids and other cell debris within the vessel 
wall [31]. 
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Figure 8 - Atherosclerotic process from the lesion formation to the foam cell formation. Legend: MCSF| Macrophage colony-
stimulating factor; MCP-1| Monocytes chemotactic protein-1; VLA4 and β2| Integrins; TNF-α| Tumour necrosis factor-α; INF-ϒ| 
interferon-ϒ; MPO myeloperoxidase. Image obtained from Ribeiro et al [31].  
 
 
 
 
Macrophages use scavenger receptors like CD36 and scavenger receptor type A (SR-A) to 
recognize and phagocyte modified and aggregated LDL. Oxidized LDL consist of free 
cholesterol as well as cholesterol esters that are hydrolyzed in lysossomes. Free cholesterol has 
a number of potential metabolic fates, including esterification by acylCoA: cholesterol 
transferase A1 (ACAT-1) and storage in the lipid droplets that characterize foam cells. 
Macrophages are normally protected from the accumulation of toxic cholesterol loads by 
multiple mechanisms, notably the down-regulation of surface LDL receptor and inhibition of 
proteolytic activation of the sterol regulatory element-binding protein (SREBP) transcription 
factors required for cholesterol biosynthesis.  However, oxidized or otherwise chemically 
modified LDL can be taken up by alternate “scavenger” or “oxidized LDL” receptors that are 
not similarly suppressed when the cholesterol load is in excess, leading to a continuous flux of 
the LDL and an continuous accumulation of it in the cells, turning them, thereby, a foam cell 
and drive an inflammatory gene expression in macrophages. Once activated, macrophages 
secrete a number of inflammatory mediators, such as several cytokines such as TNF-α, some 
interleukins (IL), as IL-12, IL-6, IL-1β, leukotrienes and several chemokines such as MCP-1, 
IL-8 and macrophage inflammatory protein 3-α (MIP-3α) that amplify inflammation in the 
vessel wall and contribute to additional recruitment of monocytes, neutrophils and other 
inflammatory cells. In addition to the production of inflammatory mediators, macrophages 
activation results on the induction of several bactericidal systems such as the Nicotinamide 
Adenine dinucleotide (NADPH) oxidase enzymes that can damage host tissue due the capacity 
of superoxide anion and other free radicals produced, to cause the deoxyribonucleic acid (DNA) 
degradation and inactivation of metabolic enzymes; the release NO which combined with 
superoxide, generate peroxynitrite that causes cell injury; the generation of reactive nitrogen 
species (RNS) from MPO that contributes to the conversion of LDL to an atherogenic form; 
expression of nonspecific esterase, lysossomal hydrolases, ectoenzymes; the secretion of an 
array of cathepsins and matrix metalloproteinases (MMPs) [30, 32].  
Besides the macrophage activation in the atherosclerotic plaques, there is the impairment of 
the macrophage functions, which is critical for the control and resolution of the inflammation. 
An important function of macrophages under both resting and inflammatory condition is the 
rapid uptake of apoptotic cells from tissues, termed efferocytosis, whose is mediated by a range 
of receptors such as CD36 and cell membrane bound tyrosine Kinase. Nevertheless, in an 
atherosclerotic lesion a chronic apoptosis of lipid-filled foam cells combined with defective 
efferocytosis contributes for the formation of the necrotic core and the progression of the 
atherosclerotic  lesion [32].  
The transition from a relatively simple fatty streak to a more complex lesion (mature 
plaque) is characterized by the migration of smooth muscle cells from the media layer (tunica 
media) of the artery wall into the intima layer. Intimal smooth muscle cells proliferate and takes 
modified lipoproteins, contributing to the foam cell formation, and the synthesis of ECM that 
lead to the development of a fibrous cap [10].  
The development of a fibrous cap can be observed in the Figure 9. According with the same 
figure, the interactions between macrophages foam cells with lymphocytes (Th1 and Th2) 
establish a chronic inflammatory process. Cytokines secreted by lymphocytes and macrophages 
exert both pro- and anti-atherogenic effects on each of the cellular elements of the vessel wall. 
Smooth muscle cells migrate from the media portion of the arterial wall, proliferate and secrete 
extracellular matrix proteins that form a fibrous plaque [10]. 
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Figure 9 - Progression of an atherosclerotic lesion and the formation of a fibrous cap. Legend: IL| Interleukin; Th1 and 
Th2|Lymphocytes; CD40| Scavenger receptor. Image obtained from Glass et al [10]. 
 
 
 
 
 
 
 
 
 
 
Mature plaques, also known as atheromas, have a more complex structure than fatty streaks 
(Figure 10). In the centre of a plaque, foam cells and extracellular lipid droplets form a core 
region that is surrounded by a cap of smooth muscle cells and a collagen rich matrix. Other cell 
types present include dendritic cells (DCs), mast cells, a few B cells and natural killer T (NKT) 
cells. The shoulder region of the plaque, which is where it grows, and the interface between the 
cap and the core, has a particularly abundant accumulation of T cells and macrophages. Many of 
these immune cells show signs of activation and produce pro-inflammatory molecules. With 
time, the plaque can progress into an even more complex lesion (unstable plaque), which the 
thinning of the plaque followed a disruption of the cap can lead to a thrombosis event and many 
of the adverse clinical outcomes associated with atherosclerosis [33].  
According with the Figure 10, the atherosclerotic plaque has a core containing lipids 
(esterified cholesterol and cholesterol crystals) and debris from dead cells. Surrounding it, a 
fibrous cap containing smooth muscle cells and collagen fibres stabilizes the plaque. Immune 
cells including macrophages, T cells and mast cells populate the plaque, and are frequently on 
an activated state. They produce cytokines, proteases, pro-thrombotic molecules and vasoactive 
substances, which all can affect the plaque inflammation and vascular function. Until 
complication occurs, an intact endothelium covers the plaque [33]. 
 
Figure 10 - Cellular composition of an atherosclerotic plaque. Image obtained from Hansson et al [33]. 
 
 
 
 
 
 
 
 
 
 
1.2.4. Plaque rupture and formation of an occlusive thrombus 
As discussed previously, although atherosclerotic lesions can lead to ischemic symptoms 
due the progressive narrowing of the vessel, acute cardiovascular events that result in 
myocardial infarction and stroke generally result from a plaque rupture and a thrombosis event 
[10].
 
According with some studies, the plaque rupture occurs in approximately 75% of fatal 
cardiac events [34].  
The transition from a stable plaque to an unstable plaque involves the rupture. The 
vulnerable atherosclerotic plaque has also been called a “high-risk” or “thrombosis-prone” 
plaque. These plaques typically are composed by a thin inflamed fibrous cap covering a lipid-
rich necrotic core and a highly thrombogenic material rich in tissue factor, one of the most 
potent pro-coagulants. Once this fibrous cap is the only barrier separating the circulation, the 
thickness and the integrity of the fibrous cap overlying the lipid-rich core is a principal factor in 
the stability of the plaque. Plaques prone to rupture can be characterized as having thinner 
fibrous caps, especially in the shoulder region, increased number of inflammatory cells, and a 
relative small number of smooth muscle cells. Plaque instability, erosion and consequent 
rupture occur due a degradation rate higher than a regeneration rate, which it owes to an 
insufficient production of ECM proteins due to the paucity of smooth muscles cells in the 
atheroma and an overproduction of MMPs through the activated cells. Plaque rupture exposes 
plaque lipids and tissue to the blood, initiating the coagulation cascade, platelets adherence, and 
thrombosis (Figure 11) [34, 35]. 
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Figure 11 - Plaque rupture and thrombosis. Image obtained from Hansson et al [33].  
 
According with the Figure 11, necrosis of some macrophages and smooth muscle cells-
derived foam cells leads to the formation of a necrotic core and an accumulation of extracellular 
cholesterol. Immune cells including macrophages, T cells and mast cells when activated can 
release pro-inflammatory cytokines, which reduce collagen formation and induce the expression 
of tissue factor. Proteases that attack the collagenous cap are also released by activated immune 
cells. The weakened plaque might fissure when subjected to the forces of arterial blood pressure 
(hemodynamic forces). Exposure of sub-endothelial structures and pro-coagulants such as tissue 
factor, promotes platelets aggregation and thrombosis. A thrombus forms and might occlude the 
lumen of the artery, leading to the acute ischemia [33]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 – Chemical structure of Hcys. Image obtained from Royal Society of Chemistry [41].  
1.3. Homocysteine 
Homocysteine (Hcys) is strongly correlated with the onset of some diseases, namely 
atherosclerosis. The first abnormality in the Hcys metabolism was described in 1962 in mentally 
retard children and associated to frequent thromboembolic events. A few years later, McCully 
(1969) described the main feature of this vascular pathology, denoted homocystinuria.  Later, 
Wilken and Wilcken mentioned, for the first time in 1976, the frequent association between 
abnormal plasma Hcys levels and CHD [36]. 
It is estimated that up to 40% of the population at risk for CVDs has elevated levels of 
Hcys. Elevated plasma levels of Hcys lead to atherosclerosis either by directly affecting lipid 
metabolism and transport or via oxidative damage. Hcys is a non- dietary sulphur-containing 
amino acid (Figure 12), which is not incorporated into proteins, but exclusively formed as an 
intermediary product of the methionine (Met) metabolism. It is produced during the conversion 
of the methionine, an essential dietary amino acid, to glutathione, a powerful antioxidant used 
by our organism to cope with oxidative stress [37-41]. 
 
 
 
 
 
 
 
 
Through the action of methionine adenosyltransferase, methionine is converted to S-
adenosylmethionine (SAM) that is the major biological methyl donor required for numerous 
cellular processes, including the methylation of nucleic acids, proteins (formation of creatinine), 
polysaccharides and phospholipids. These reactions are catalyzed by various methyltransferases 
that demethylate SAM to S-adenosylhomocysteine (SAH), which is the immediate precursor of 
Hcys [40, 42]. The hydrolysis of the SAH by the SAH hydrolase leads to the formation of 
homocysteine and adenosine [43].
 
 Once Hcys is generated, it may be recovered to Met by 
methylation, or degraded to cysteine by transsulphuration. Remethylation to Met is catalysed in 
most tissues by the ubiquitous enzyme, methionine synthase (MetS), which uses vitamin B12, as 
cofactor, and 5-methyltetrahydrofolate, a derivate compound of folate (vitamin B9), as a methyl 
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Figure 13 – Homocysteine metabolism pathways. Image obtained from Hoffamn [42]. 
 
donor. Met can also be formed from Hcys by betaine-homocysteine methyltransferase and using 
betaine as a methyl donor. However, this reaction is probably confined to the liver and possibly 
to the kidney. About the transsulphuration, two vitamin B6-dependent enzymes are involved. 
The enzyme cysthathionine β-synthase (CBS) first condenses Hcys with serine to form 
cystathionine, which is then cleaved into cysteine and α-ketobutyrate by cystathionine ϒ-lyase 
(CL). Cysteine may be utilized in the synthesis of proteins or as a precursor of the antioxidant 
glutathione [40]. Changes in the concentration of Met in the body, particularly as a result of its 
dietary intake, affect the rate of SAM synthesis, as well as the metabolism of Hcys [43].  A 
simplified overview of this complex metabolic pathway can be observed at the Figure 13. 
According to it, Hcys is remethylated into methionine using 5-methylhydrofolate (5meTHF) as 
a methyl donor and vitamin B12 as a cofactor. Met is transformed into SAM, a key intermediate 
in one-carbon metabolism. Hcys is removed from this cycle in a B6-dependent process leading 
to production of cysteine. Cysteine can be catabolised or incorporated into proteins or used to 
the formation of glutathione [42]. 
 
 
 
 
 
 
 
 
 
 
 
 
Under normal metabolic circumstances, there is a strict balance between Hcys formation 
and elimination. Usually about 50% of the Hcys formed is remethylated to Met. When protein 
or Met intake is in excess, a large proportion is catabolised by the transsulphuration pathway. If 
Figure 14 – Various forms of Homocysteine in blood. Image obtained from Nygard et al [40]. 
 
there is an increased formation of Hcys relative to its consumption, Hcys is excreted from the 
cells, and this can be detected as an increased level of Hcys in plasma/serum or, even in the 
urine [40]. 
Hcys concentration, in plasma or serum, normally, is about 5-10 μmol/L, because only a 
little amount (~1%) is in reduced form whereas the most part is oxidized and exists as various 
disulphides (Figure 14). In these dimmers, about 20% appears to be in its free form while the 
most part (80%) is bound to plasmatic proteins, mainly albumin. However, under abnormal 
situations, the Hcys metabolism becomes deregulated,  total Hcys levels starts to rise and the 
reduced form starts to be predominant [40]. 
 
 
 
 
  
 
 
  
 
An elevated level of blood Hcys concentration, or hyperhomocysteinemia (HHcys), is 
divided into three categories: mild (15 - 30 μmol/L), intermediate (30 - 100 μmol/L) and severe 
(> 100 μmol/L) [36]. 
  
1.3.1. Causes of hyperhomocysteinemia  
There are many determinants causes for an elevated blood level of Hcys in humans: 
A. Genetic determinants:  
Although recently more than fifteen different genes are under investigation for their 
relationship to plasma total Hcys levels, there are three genes whose alterations or deficiencies 
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have being already associated with HHcys. These genes code for the enzymes CBS, MetS and 
Methylenetetrahydrolate reductase (MTHFR) [37]. 
CBS deficiency, an autosomal recessive disorder, is the most common cause of 
homocystinuria. Individuals heterozygous for CBS deficiency (between 1 in 200 in the general 
population) have normal Hcys levels in 30 to 50% of cases [37]. Remain patients with CBS 
deficiency have extremely high levels of Hcys in the plasma (300-400 μmol/L) and in the urine. 
Their clinical condition can involve the displacement or malposition of the crystalline lens of 
the eye (ectopia lentis), osteoporosis, skeletal anomalies, mental retardation and a high 
incidence of premature vascular episodes (arterial and venous thrombosis and premature 
atherosclerosis) [40, 44].  
The most common form of genetic HHcys results from the production of a thermolabile 
variant of MTHFR with an enzymatic activity around 50% (C677T mutation). Homozygosity 
for this mutant enzyme is present in 9% to 17% of the population, and heterozygosity can be 
detected in 30% to 41% of the general population.  However, there is a substantial interethnic 
variation. In the population of African descent, Asian Indians or Canadian Inuit, the prevalence 
for homozygous is 0-2%, whereas it may be about 20% in Asians and even higher in Northern 
Italy. This difference may partly explain by the variable Hcys levels according to ethnicity. 
Remarkably, in homozygous individuals, the autosomal recessive mutation in MTHFR 
provokes a moderate HHcys because the mutated enzyme has a reduced binding to their 
substrate folate. Folate deficiency could be partially responsible for the expression of the 
MTHFR thermolabile genotype, as it favours the undesired incorporation of uracil instead 
thymine into the human DNA [45]. On the other hand , if there is a  genetic MTHRF 
suppression, severe HHcys occurs and all the problems associated with that, such as 
thromboembolic vascular disease even in childhood [37, 40]. 
Five known mutations affect methylcobalamin synthesis, an essential cofactor of MetS. 
These mutations induce a functional deficiency in MetS that leads to intermediate HHcys and 
hypomethioninemia (low levels of methionine). The functional deficiency depends on the 
mutations in the MetS gene or in the gene encoding MetS reductase, an enzyme involved in the 
reductive activation of MetS. This gene shows a common polymorphic form (276G) that 
changes the crucial binding site of the coenzyme (Vitamin B12) and therefore might influence in 
the secondary structure with a possible reduced functional activity. This mutation is rare and is 
associated with intermediate and severe HHcys [37].  
 
B. Physiological determinants: 
HHcys levels are influenced by gender, being higher in men than in women. The difference 
between the genders becomes apparent in the puberty and is believed to be related to hormonal 
factors, but also to the lifestyle, diet and vitamin status. It is also believed that Hcys is higher is 
men than woman due muscular physiology, as creatine/creatinine synthesis is obtained from 
SAM methylation with the formation of Hcys [40]. Nygard et al (1998) demonstrated that Hcys 
levels are about 1.65 times higher  in men  than in women [46]. 
The total Hcys concentration decreases in normal pregnancies but higher levels are 
observed in pregnancies complicated by recurrent spontaneous abortions or placental coating 
separation from the uterus  [40].  
The levels of Hcys are strongly related to the renal function. The renal function plays a 
central role for the clearance of Hcys, and because the urinary excretion of Hcys is low,  
Guldener (2006) suggested that an extensive metabolism of Hcys, probably the transsulfuration, 
takes place in the kidney [47]. The normal physiological decline in the renal function by age and 
may to some extent explain the increase in Hcys with age  [40]. 
C.  Nutritional determinants: 
Dietary intakes and plasma levels of folate and vitamin B12 are inversely related to the total 
Hcys concentration. Deficiencies of these vitamins may cause a moderate or even severe 
HHcys. Therefore, an increased total Hcys level is a sensitive marker of the disturbed function 
of both folate and vitamin B12 metabolism. The association between vitamin B6 deficiency and 
HHcys is, however, less clear, pointing to an inverse correlation.  
D. Lifestyle: 
Some studies analyzed the influence of various aspects of lifestyle on the Hcys levels, as 
smoking, coffee and alcohol consumption. It was observed that smoking and heavy coffee 
consumption are associated with elevated Hcys levels, whereas physical activity is associated 
with low Hcys [39, 48]. It was also detected that moderate alcohol consumption may be 
associated with reduced Hcys levels, whereas a chronic high alcohol consumption is linked to 
elevated Hcys, possible via impaired folate or vitamin B6 function [39].  According with 
Dwivedi, et al (2011), Hcys levels are about 1.91 times higher in heavy smokers (>20 cigarettes 
per day) than in non-smokers. Likewise, Hcys levels were also elevated two-fold in high alcohol 
consumers (>1.5g/Kg/day) compared to non-consumers  [37].  
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E. Drugs: 
A number of drugs influence Hcys levels by interfering with its metabolism. Folate 
antagonists (as methotrexate) and vitamin B12 antagonists (as NO), may lead to a noticeable 
Hcys elevation. The utilization of some immunosuppressive drugs (as cyclosporine), causes a 
moderate increase in Hcys levels. Antidiabetic drugs (as metformin), may elevate Hcys by 
affecting folate as well as vitamin B12 levels. Anticonvulsant drugs used in the epileptic 
treatment, cause elevated Hcys levels by interfering with folate polyglutamation and retention.  
Hypolipidemic drugs, such as colestipol niacin and cholestyramine, may elevate Hcys by a 
folate-antagonistic effect. Theofylin and azaribine also increase Hcys levels through the 
inhibition of vitamin B6 function. Markedly, azaribine, a drug previously used in the psoriasis 
treatment, was related to an increased incidence of thromboembolism, being prohibited by the 
Food and Drug Administration (FDA) in 1976. Some anti-Parkinson drugs, such as L-dopa, 
becomes methylated by SAM and may therefore to increase the levels of Hcys by enhancement 
of its production. Several hormones-related drugs may influence the Hcys levels. In women, 
Hcys levels are lowered by some anti-hormones (tamoxifen), by hormone replacement therapy 
and some oral contraceptives, and increased by the androgen administration. In men, oestrogen 
plus antiandrogen administration has a substantial effect on Hcys lowering. Aminothiols such as 
penicillamin, acetylcysteine, and ifosfamide (associated with the use of mesna, which is a drug 
that is used with to prevent an adverse reaction of ifosfamide called haemorrhagic cystitis or 
hemorrhagic inflammation of the bladder) reduce Hcys levels probably by increasing renal 
clearance or by displacing Hcys from the protein binding sites. Such drugs have been suggested 
for the treatment of homocystinuria [40]. 
F. Diseases: 
Some pathological conditions are associated with elevated Hcys levels. This can usually be 
explained by low vitamin status, impaired enzyme function and/or renal failure [40]. 
Hyperproliferative disorders, such as acute lymphoblastic leukemia and severe psoriasis are 
associated with elevated Hcys levels, probably explained by an increased Hcys export from the 
proliferating cells [40, 49, 50] . Hypothyroidism is also associated with an increased prevalence 
of HHcys due the decrease of hepatic levels of enzymes involved in the remethylation [51]. 
Acute hyperinsulinemia is associated with a decrease in Hcys concentration in normal 
individuals [52]. In diabetes mellitus, elevated Hcys levels is observed simultaneous with the 
onset of nephropathy, once the reduced metabolic capacity of the kidney tissue might be rate 
limiting for renal Hcys clearance [53].   
 
Figure 15 - Hcys oxidation. Legend: RS-H| Hcys; Tmx+| transition metal; RSSR| Disulphide; O2
.-| Superoxide anion radical; SOD| 
Superoxide dismutase; H2O2|Hydrogen peroxide. Image obtained from McDowell et al [57]. 
 
 
1.3.2. Hcys and atherosclerosis  
Apart from the conventional risk factors for CVDs, elevated levels of plasmatic Hcys is now 
considered to be an independent risk factor for atherosclerosis and thrombosis. Some studies 
have suggested that HHcys can promote atherosclerosis via oxidative stress by the generation of 
ROS, and via the cellular impairment through the DNA hypomethylation and the N-
homocysteinylation. 
1.3.2.1.  Hcys and oxidative damage  
Oxidative stress induced by HHcys may occur as a result of the decreased expression and/or 
the activity of key antioxidants enzymes as well as an increased enzymatic generation of 
superoxide anion (the precursor for multiple ROS and RNS) [54]. Hcys contains a reactive 
sulfhydryl group (RS-H) and, like most thiols, can undergo oxidation to a disulphide (RS-SR) at 
physiological pH in the presence of oxygen (O2) [55]. The general reaction is catalyzed by 
transition metals, and a variety of ROS can be produced, including superoxide anion radical and 
hydrogen peroxide (Figure 15) [56, 57]. 
 
 
 
 
 
 
 
 
Once the superoxide is produced, superoxide can enter the cells and the organism tries to 
deal with it by the action of an enzyme endothelial superoxide dismutase (eSOD). However, 
superoxide can readily react with NO to form the oxidant peroxynitrate (OONO
.
). This reaction 
is five-fold faster than superoxide radical degradation by SOD, leading to a decreased 
bioavailability of NO at the endothelial cells [57]. This occurrence, associated with some others 
deleterious actions of the oxidative damage of the Hcys, illustrated in the Figure 16, starts a 
vicious cycle of ROS generation, which leads the cell to a dead end characterized by an 
inflammatory activation and for last an apoptosis process [37, 58]. According with this figure, 
HHcys also provokes the decrease secretion and expression of SOD, the formation of S-
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Figure 16 - Hyperhomocysteinemia and oxidative stress. Hcys might directly or indirectly (altered DNA methylation) lead to oxidative 
stress via the pathways shown in the figure.  Legend: NO| Nitric oxide; M+|Transition metal; GPX| Gluthatione peroxidase; EC-SOD| 
Extracellular superoxide dismutase; PRMT 1| Protein Arginine N-Methyltransferase 1; H2O2| Hydrogen peroxide; O2
-| Superoxide; 
ONNO.| Peroxynitrate; PAI 1| Plasminogen Activator Inhibitor 1; VCAM| Vascular Cell Adhesion Molecule;  ICAM-1| Intercellular 
adhesion molecule-1  MCP1| Monocytes chemoattractant protein-1; eNOS| Endothelial NO synthase; NOS| NO Synthase; ADMA| 
Asymmetric dimethylargigine. Image adapted from Sharma et al [39]. 
 
nitroshomocysteine, the inhibition of gluthation peroxidase (GPX-1), the depletion of 
intracellular glutathione and the accumulation of asymmetric dimethylargigine (ADMA) or even 
inhibiting tetrahydrobiopterin (a cofactor of eNOS) [39].  
 
 
 
 
 
 
Besides the resulting effects of the oxidant stress of Hcys into the cells, ROS generated by 
the increased concentration of auto-oxidized Hcys, can incite the LDL peroxidation into the 
vessels walls by the reduction of the copper (Cu) in the Ceruloplasmim (Cp). Cp is an abundant 
plasma protein (300 μg/mL) that contains seven copper atoms per molecule and accounts for 
95% of the total circulating copper in healthy adults [59]. The physiological function of Cp is 
uncertain but it is believed that this protein has an important role in copper transport, 
coagulation, angiogenesis, antioxidant action, and iron homeostasis. Reduction of Cu
2+
 to Cu
+
 of 
the Cp by superoxide radicals produced by the Hcys auto-oxidation may trigger the LDL 
oxidation activity of this protein [37, 60]. 
Thus, these reactive species generated cause an oxidative stress inside the cells, which can 
cause some cellular deregulations that contribute for the endothelium dysfunction, inflammation 
and oxidant injury [61]
 
. Au-Yeung et al (2004) showed that Hcys damages endothelial cells by 
increasing ROS production, affecting antioxidant defence systems, promoting lipid 
peroxidation, as well as triggering apoptosis via mitochondrial oxidant production [62]. Hcys 
also promotes production of ROS by isolated monocytes and platelets [42]. Likewise, it is 
believed that Hcys can also deregulate the biosynthesis of cholesterol by hepatic cells due to 
homocysteine-induced endoplasmic reticulum stress. However, the exact mechanisms involved 
in all these harmful events still remain poorly understood [58, 63]. 
1.3.2.2. Hcys and hypomethylation 
Associated with the oxidant effect of Hcys, some effects at the genetic level are also 
provoked by an elevated level of Hcys and they may have a lethal role on cell. DNA 
methylation is a critical component of epigenetic regulation of the gene expression. DNA 
hypomethylation is induced by increased Hcys levels and decreased level of Met. Thus, global 
or selective DNA methylation alteration may contribute to alteration in gene expression and 
vascular changes during HHcys. Hcys at high concentration also increase the transcription and 
activity of tissue factor. Hcys elicits a DNA damage response in neurons that promotes 
apoptosis and hypersensitivity to excitotoxins. DNA strands breaks and associated activation of 
PARP [poly (ADP-ribose) polymerase] and NAD (nicotinamide adenine dinucleotide) depletion 
occur rapidly after exposure to Hcys and precede mitochondrial dysfunction, oxidative stress 
and caspase activation [64]. 
1.3.2.3. Hcys, Hcys-thiolactone and N-homocysteinylation  
Recent studies found that the most reactive form of Hcys, which modifies haemostasis, 
including biological proprieties of blood platelets, may be Hcys- thiolactone (HTL), which 
represent 0.29% of the total Hcys plasma levels. In all organisms, Hcys is metabolized to the 
thioester-Hcys-thiolactone in an error-editing in protein biosynthesis when Hcys is selected in 
place of methionine by methionyl-tRNA synthetase and paraoxonase 1. HTL levels (≥ 15.3 
μmol/L) are elevated in HHcys. HTL, known to be cytotoxic in experimental animals and cell 
cultures, is harmful mostly because of its ability to form isopeptide bonds with protein lysine 
residues. N-Hcys-proteins, including - fibrinogen may be linked to human pathology such as 
atherosclerosis (Figure 17). N-homocysteinylation exist in endothelial cells proteins, involves 
acylation of lysine amino group by the activated carboxyl group of HTL, and depends on the 
concentration of Hcys [65, 66].  
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Figure 17 - Hcys-thiolactone metabolism. A| Hcys-thiolactone (HTL) formation; B| N-homocysteinylation. Image adapted from 
Manolescu et al [67]. 
 
 
 
 
 
 
 
 
 
   
 
Generally, N-homocysteinylation alters the function of the proteins through the introduction 
of new free thiol group, and the inactivation of free amino groups, affecting the overall redox 
potential of the proteins. Moreover, it has been found that proteins modified through this 
mechanism can act as neo-antigens, triggering the endothelium injury and the activation of the 
inflammatory response, a key component in atherogenesis, atherothrombosis and stroke. 
Furthermore, HTL impairs the ability of the vascular endothelium to regenerate itself through 
the direct inhibition of lysyl oxidase that is responsible for the correct cross-linking/reticulation 
of the collagen and the elastin into the artery wall [67]. 
Malinowska et al (2012) showed that HTL modulates the platelet adhesion to the collagen 
and the fibrinogen, promoting the adhesion of the thrombin-activated platelets to the collagen, 
when platelets were treated with a high concentration of Hcys (50 and 100 μmol/L). This study 
also demonstrated that HTL is more effective modulator of the platelet adhesion than Hcys. 
Therefore, the authors conclude that HTL, even at lower concentration than Hcys may be an 
additional factor which leads to the significant increase of cardiovascular risk. Likewise, they 
have shown that a combination of Hcys and HTL had even greater modulation action on the 
platelet adhesion than any of tested thiol compound alone [66].  
 
1.3.3. Hyperhomocysteinemia, vitamin B-cofactor and lowering therapies 
As already referred, vitamins B-cofactors (folate, vitamin B6 and vitamin B12) play an 
essential role in Hcys metabolism; particularly the catabolic enzymes CBS and CL require 
vitamin B6 and the remethylation enzyme (MetS) require vitamin B12 and folate for its catalytic 
activity. It is therefore evident that there is an inverse correlation between Hcys levels and with 
folate and vitamin B levels (Fig. 13). This strong metabolic relationship is particularly relevant 
in the quantification of Hcys levels in HHcys conditions  and a strong incentive to investigate 
folate, vitamin B6 and B12 levels in Hcys lowering therapies [40, 68]. This is not, however, a 
consensual issue as the role of folic acid, vitamin B6 and B12 supplementations in the prevention 
of CVDs events is not yet fully understood. Although some studies have shown a relationship 
between the use of vitamin B-cofactors supplements for lowering Hcys level [69-71] most of 
them  have suggested that the existing evidence indicates that the Hcys lowering therapies of the 
folic acid, vitamin B6 and B12 do not lower the risk of CVD. This context is clearly illustrated in 
the review from Clarke, et al (2010) in which they performed a meta-analysis of 8 randomized 
trials involving 37485 individuals with increased risk of CVD and concluded that doses of folic 
acid (ranging from 0.8 to 40 mg/day) can reduce Hcys levels in 25%. However, in the same 
review, the authors also concluded that dietary supplementation with folic acid to lower the 
Hcys levels had no significant effects in cardiovascular events or on overall cancer or mortality 
in the population studied within a 5 years period [72]. Regarding this, the American Heart 
Association guidelines for CVD prevention do not recommend the use of folic acid 
supplementation to prevent CVDs.  Some potential causes responsible for the lack of consensus 
between these trials could be the difference between the study groups. Hcys concentrations, 
inclusion of patients from countries that do not have regulations about the food enrichment with 
the folic acid, trial period, composition of the vitamin formulation, gender distribution, other 
patients’ medication and patient’s disease, among others, lie behind this lack of consensus [67, 
73].  
1.4. Vitamin B-cofactors 
Vitamin B-cofactors play an important role on the strict balance of the Hcys metabolism. 
Their deficiencies can promote an accumulation of Hcys in the organism and contribute for the 
development of hyperhomocysteinemic conditions and associated pathological situations.   
1.4.1. Vitamin B6  
 
Vitamin B6 is a water-soluble vitamin, and occurs in three closely related compounds with 
similar physiological actions, pyridoxine, pyridoxal and pyridoxamine. The first is found in 
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Figure 18 - Pyridoxine and Pyridoxine 5’-phospate structures. Image adapted from Royal Society of Chemistry [75, 76].  
  
large quantities in plant sources and the other two in animal tissues. Liver, grain cereals, peanuts 
and bananas are rich in vitamin B6. In humans, vitamin B6 is also obtained from several 
intestinal microorganisms able to synthesize this vitamin. Adult requirements are about 
2mg/day. The biological active form of Vitamin B6, pyridoxal 5’-phoshate (Figure 18), 
participates in an important coenzyme system in the protein synthesis and is involved in the 
lipids and the carbohydrate metabolism. This vitamin deficiency (< 30 nmol/L or 7.4 ng/mL) 
has a serious effect on brain function, as the vitamin plays a crucial role in the synthesis of 
several neurotransmitters (serotonin, dopamine, norepinephrine, among others). The vitamin B6 
deficit contributes to the development of several neuropsychological disorders such as 
Parkinson disease, delayed dykinesia and depression. The lack of this vitamin also affects the 
immune function, resulting in impaired cell-mediated immunity and reduced antibody 
responses. Its deficiency also contributes for the development of CVDs,  as the B6 active form 
plays a key role as a coenzyme of two enzymes (CBS and CL) required for the metabolism of 
the  Hcys to cysteine [74-76]. 
 
 
 
1.4.2. Vitamin B9  
Folate or vitamin B9, is a water-soluble B vitamin present in cells as a family of structurally 
related and metabolically interconvertable enzyme cofactors that plays an important role in one-
carbon metabolism. This pathway is necessary for the synthesis of purine and thymidine 
nucleotides and for the synthesis of methionine from Hcys. Inadequate folate intake has been 
linked to the risk of anaemia, neuropsychiatric disorders, neural tube defects and CVD, by the 
elevation of Hcys concentration.  Moreover, folate deficiency leads to the incorporation of 
uracil instead of thymine into human DNA and to an increased frequency of chromosomal 
breaks, causing disruption of DNA synthesis, repair and methylation, which may increase the 
Figure 19 - Structure of the Tetrahydrofolate triglutamate. Legend: The blue fraction of the structure corresponds to the folate 
monoglutamate. Image adapted from Park et al [77].  
 
risk to develop some cancers. Important food sources of folate include vegetables, especially 
green leafy vegetables, cereals, fruits, nuts, seed, liver and its derived products [45]. Dietary 
folates predominantly exist as polyglutamates (Figure 19), which have to be hydrolyzed to 
folate monoglutamates by the folate reductase in the jejunal mucosa in order to be absorbed. 
Folate polyglutamates comprises a chemically reduced pteridine moiety that is likened to p-
aminobenzolglutamate through a methylene group [77]. 
 
 
 
 
 
 
 
 
 
Once absorbed, inside the enterocytes cells, folate monoglutamates are transported into 
mitochondria and are processed into functional metabolic cofactors by the addition of ϒ-linked 
polyglutamate peptide that ranges from 2 to 9 glutamate residues in length. Tetrahydrofolate 
(THF) polyglutamates chemically activate and carry one-carbon units at the oxidation levels of 
5-formyltetrahydrofolate, 10-formyltetrahydrofolate, methylenetetrahydrofolate and 5-
methyltetrahydrofolate (5-methylTHF).  Each one-carbon form of folate is a required cofactor 
for one or more biosynthetic pathways (Figure 20), with the exception of 5-
formyltetrahydrofolate, which does not serve as a metabolic cofactor and may be a storage form 
of folate. These metabolites have different roles, being 10-formyltetrahydrofolate required for 
the synthesis of the purine ring; methylenetetrahydrofolate is required for the conversion of 
deoxyuridine monophosphate to deoxythymidine monophosphate (dTMP), which in turn is used 
in DNA building; and 5-methyltetrahydrofolate is required for the remethylation of Hcys to 
methionine [77]. 
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Figure 20 - Folate metabolism. Folate metabolism is required for purine, thymidylate and methionine biosynthesis. Legend: 1| 10-
formylTHF synthetase; 2| 10-formyTHF dehydrogenase; 3| MethenylTHF synthetase (MTHFS); 4| Serine hydroxymethyltransferase 
(cSHMT); 5| MethyleneTHF dehydrogenase (MTHFR); 6| Methionine synthase (MS)   Image obtained from Park et al [77]. 
 
 
 
 
 
 
 
 
 
 
 
 
Following the formation process of THF polyglutamates inside the enterocytes, 5-
methyTHF is released into the portal circulation, being the main folate form in the plasma. 
Much of this folate is taken by the liver, although some is released into the bile where it is 
recirculated by the enterohepatic cycle. Deficiency of 5-methylTHF is considered when plasma 
levels are lower than 10 nmol/L (4 ng/mL) [78, 79]. 
 Folic acid, a folate monoglutamate, is a stable, synthetic analog, which is merely the parent 
structure of this large family of vitamin coenzymes. Due the only single glutamate in its 
structure, folic acid is absorbed more efficiently, exhibiting greater bioavailability than naturally 
occurring folate, which assumes, as already referred, the polyglutamate form [77].  The relative 
bioavailability of dietary folate is estimated to be only 50% when compared with the synthetic 
folic acid [80]. 
 
 
 
 
Figure 21 - Cobalamin structure. Image obtained from Royal Society of Chemistry [82]. 
 
1.4.3. Vitamin B12 
Vitamin B12 or cobalamin (Figure 21) plays an important role in the DNA synthesis and 
neurological function. Vitamin B12 is a cobamide (cobalt-containing corrins), which is a 
presumed archetype of tetrapyrrole (family of compounds which has evolved to exploit the 
special properties of the ionic forms of cobalt, iron, magnesium and nickel) [81, 82]. The usual 
dietary sources of vitamin B12 are mainly animal food (chicken, mutton and liver), eggs, fish 
and shellfish [83]. This vitamin is also produced by the most species of enteric bacterias, as 
Salmonella, Escherichia and Enterobacter species  [84]. 
 
 
 
 
 
 
 
 
Cobalamin deficiency (low serum level, usually, less than 74 pmol/L or 100 pg/mL) is 
associated with hematologic, neurologic, and psychiatric manifestations. It is a common cause 
of macrocytic (megaloblastic) anemia and, in advanced cases, pancytopenia (leukopenia or 
reduction of leukocytes number and thrombocytopenia or reduction of platelets number). 
Neurologic sequels from cobalamin deficiency include paresthesias (skin feelings of tingling, 
tickling, stinging and burning), peripheral neuropathy, and demyelization of the corticospinal 
tract and dorsal column. This vitamin deficit has been also linked to psychiatric disorders, 
including impaired memory, irritability, depression, dementia and, rarely, psychosis. In addition 
to these hematologic and neuropsychiatry manifestations, vitamin B12 deficiency may exert, like 
folate deficit, indirect cardiovascular effects by increasing  the Hcys levels  [85]. 
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Figure 22 - Cobalamin absorption and transport. Image obtained from C. Robert et al [85].  
 
Vitamin B12 can be absorbed by two pathways: intrinsic factor (active diffusion)  and 
passive diffusion [83]. The first one is used for the absorption of large amounts of vitamin that 
normally enter the organism by ingested food [83]. Once ingested, the acidic environment of the 
stomach facilitates the breakdown of cobalamin that is bound to food. An intrinsic factor 
(gastric intrinsic factor), a glycoprotein that is released by parietal cells in the stomach, binds to 
vitamin B12 in the duodenum [83, 85] and this complex subsequently aids on the absorption of 
the vitamin in the terminal ileum (Figure 22). The other pathway (passive diffusion) is normally 
used for small amounts of vitamins [83] Once absorbed, cobalamin binds to transcobalamin II 
and is transported throughout the body [85]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5. Hcys and vitamin B-cofactors: analytical determination  
The determination of the total Hcys levels has gained high interest within the biomedical 
community over recent years as the molecule was considered an important biomarker for a wide 
range of diseases, especially atherosclerosis. Associated to Hcys metabolism, the vitamin B-
cofactors are also interesting molecules to quantify, allowing obtaining a better overview of 
Hcys levels and possible causes of their abnormal levels. Regarding this, only very recently a 
study using HPLC for the simultaneous quantification of vitamin B-cofactors (B6, B9 and B12) 
and Hcys in human serum has been reported [86]. In other previous study, simultaneous 
quantification of folate and Hcys has been performed using LC coupled to tandem mass 
spectrometry (LC/MS/MS) detection [87, 88]. Beyond these reports,  vitamins B-cofactors and 
Hcys are usually quantified individually most commonly using radioimmunoassay [89, 90] and 
competitive chemioluminescent enzyme immunoassays [91] (for folate and vitamin B12), and 
HPLC (for vitamin B6) [89, 91, 92] .  
Regarding the analytical measure of Hcys, several types of methods are actually available 
for its determination in the plasma. Among them, some are nearly obsolete like radioenzymatic 
determination, whereas chromatographic methods are still used and immunoassays become 
broadly employed due to their easy full automation possibilities. Table 1 summarizes the main 
features of current analytical methods to quantify Hcys (reviewed in [36]).  According to this 
table, it is possible to note different methodologies used for Hcys analysis as well as their 
advantages and drawbacks. From several methodologies presented, capillary electrophoresis 
with laser-induced fluorescence (CE-LIF) and LC/MS/MS detection are the techniques that 
allow the cheaper analysis of Hcys with high number of samples analysis performed 
(throughput). Nevertheless, these two methods present some crucial drawbacks that are essential 
for the development of the technique that aims of this study. Unlike the methodology developed 
here, CE-LIF uses derivatisation to increase sensibility and precision in Hcys analysis, requiring 
more time of analysis, LC-MS/MS requires equipment that is not available monetarily for the 
most laboratories, and both methods require usually a laborious process (high workload) for 
processing the sample.   
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Table 1 - The main characteristics of the current analytical methods. Adapted from Drucros, et al [36]. 
Method a 
Sample pre-
treatment 
Plasma 
volume 
(μL) 
Upper limit 
of linearity 
(μM) 
Coefficient of 
variation for mean 
total Hcys level (%) 
Throughput 
(test/hour or 
day) 
Reagent cost  
estimation by 
Euros b 
GC-ID-MS 
High workload 
(laborious pre-
treatment process) 
+derivatization 
100 
30-300 
 
2.6 -5.7 96-160/day 2.3 
LC-MS-
MS 
High workload 
100 60 5.9 40/h 1.0 
HPLC-FD 
High workload 
+derivatization 
60-150 50-300 3.2 - 4.8 90-150/day 5.4 
HPLC-ED High workload 
60 100 5.6 60/day  
IEC Medium workload 
599 100-1000 7.8 25-50/day 1.73 
FPIA None 
50 45-50 3.1 20-60/h 11.5 
ICL None 
15 50 3.9 150/h 11.5 
EIA Low workload 
25 50 6.2 96/2.5h 
12 (test in 
duplicate) 
Enzymatic 
method 
None/Low workload 5-100 80-100 
2.8-3.7 45/h  
CE-LIF 
High workload 
+derivatization 
100 200 7.8 100/day 0.76 
a GC-ID-MS| Gas chromatography-mass spectrometry with isotopic dilution; LC-MS/MS| Liquid 
chromatography with tandem mass spectrometry; HPLC-FD| High-pressure liquid chromatography with 
fluorescence detection; HPLC-ED| High-pressure liquid chromatography with electrochemical detection; IEC| Ion-
exchange chromatography; FPIA| Fluorescence polarization immunoassay; ICL| Chemioluminescence 
immunoassay; EIA| Enzyme-linked immunoassay; CE-LIF| Capillary electrophoresis with laser-induced 
fluorescence. 
b Taking into account neither the equipment cost, nor the technician salary.  
Immunoassays, such as fluorescence polarization, chemioluminescent microparticle and 
enzyme-linked, are the more convenient especially for large screening programs of HHcys 
detections. But knowing their limitations, high values of Hcys needed to be checked by using 
reference methods in a specialized laboratory. Moreover, this kind of analysis also shows some 
limitations about of the reagent costs and the price of the equipment[36].   
Chromatographic methods have been extensively used for the determination of total Hcys 
until the introduction of the immunoassays. Therefore, there is an abundance of 
chromatographic techniques available, using HPLC or ion-exchange liquid chromatography 
with fluorescence, Ultraviolet/visible (UV/Vis) and electrochemical detection and also 
hyphenated techniques using Gas Chromatography (GC) or LC coupled to MS detection.  All 
these techniques have shown to produce various advantages in terms of sensitivity depending on 
the conditions required and they can allow the co-determination of the other amino acids used 
for diagnosis. However, the lack of selectivity present in many of the procedures forces the 
utilization of a separation technique (pre-treatment) previously to the chromatographic 
separation. Despite the advantage of increase both selectivity and sensitivity, this often add time 
and money to the methodology, which can compromise its suitability to routine and high 
throughput clinical analysis. LC coupled with MS/MS has been proposed for Hcys 
determination due the undoubted advantages in terms of the quality of the results owing its 
specificity, sensitivity and the utilization of labelled internal standards, and because the cost of 
reagents is definitely lower than that for immunoassays. However, the cost of equipment is the 
biggest drawback to include LC/MS/MS in the routine clinical quantification [36, 55].  
1.5.1. Micro-extraction in package sorbent as a potential tool for Hcys and 
vitamin B-cofactors extraction from biological samples  
When chromatographic assays are used in the analysis of total Hcys, the most common 
technique applied for the separation of this compound from biological matrix, is a pre-treatment 
procedure named derivatisation. This is based on the bond between the derivatisation reagents 
with the Hcys, forming a complex that can be detected with more accuracy, allowing to 
differentiate Hcys from others compounds on the sample. Several studies have used some 
derivatisation reagents, such as monobromimane (mBrB), halogenosulfonylbenzofurazans 
(SBD-F and ABD-F) and o-phthaldialdehyde (OPA), to increase sensibility and precision in 
Hcys analysis. This technique allows the direct injection of processed plasma and it is usually 
used with less sensitive LC detectors, such as fluorescence and UV/Vis, or when gas-
chromatography is the selected chromatographic methodology. However, this pre-treatment 
procedure presents some drawbacks that can compromise its automation. Among them are the 
lack of specificity of the derivatisation reagents for Hcys molecule, the production of secondary 
metabolites that can interfere with Hcys determination; the incompatibility of the reduction 
reagents needed to break the sulfhydryl bonds of the disulphides in the plasma; and complex 
gradient elution programs for the proper separation the analytes, requiring a laborious method 
[36, 55].  These drawbacks are not present when accurate LC detectors, such as MS and 
electrochemical detection (EC), are used as in these cases the critical derivatisation pre-
treatment step is not required to quantify Hcys with good accuracy and precision. Recent studies 
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reported the quantification of Hcys and vitamin B-cofactor (folate) using the extractive 
technique solid phase extraction (SPE) [87], or through direct injection [88]. As stated by 
Nelson et al [87] the determination of total Hcys is difficult because of the instability of its 
reduced form and the diversity of its oxidized forms. The determination of folate is also very 
challenged due to its susceptibility to convert to other forms and to degrade during sample 
preparation. Moreover, according to the same authors, most LC/MS methods, but not all, 
depend on the selective extraction of the analytes using reversed-phase, anion exchange or 
affinity SPE. Likewise, this represents a problem because most SPE protocols are inherently 
more oriented to the extraction of Hcys or folate, but not both analytes simultaneously due to 
the differences in analyte stabilization and polarity (Hcys is strongly polar in solution while 
folates are only moderately polar). Even so, Nelson et al [87] managed to get good results in the 
simultaneous quantification of Hcys and folate by performing a two-step C18 SPE previously to 
a LC/MS/MS analysis. In turn, Persichill, et al [88] obtained a good analytical performance in 
the plasmatic Hcys and folate quantification only using protein precipitation followed by direct 
injection into the LC/MS/MS equipped with a strong cation exchange column. This 
methodology is obviously quite more simple and less expensive than the SPE method presented 
by Nelson et al [87].  Nevertheless, according with Abdel-Rehim et al [93], high matrix 
background in the extracted samples with consequent significant signal suppression is often 
observed when protein precipitation (PP) is used as a sample preparation methodology. The 
same authors also affirmed that SPE is more efficient recovering drug analytes because of the 
ability to efficiently retain highly functionalized compounds from aqueous samples and release 
them into organic solvents in the following elution step. 
Regarding this, microextraction by packed sorbent (MEPS) is a new sensitive, selective, 
accurate and promising sample extraction technique. MEPS is a development of conventional 
SPE that has miniaturized the sorbent bed so that it can be incorporated into the sample path 
without voids. MEPS is a logical extension of SPE for handling biological fluids because, 
unlike SPE, this technique uses small operating volumes that reduce the size of the sample 
required. MEPS uses the same sorbents as conventional SPE columns and so is suitable for use 
with most existing methods by reducing the volume of reagents and sample, being in this way 
more easily automated than SPE. Extraction performance is comparable to conventional SPE 
because the MEPS sorbent bed retains the same dimensional ratios of the conventional SPE 
cartridges and adaption of existing methods is achieved by converting all steps in proportion to 
the bed volumes, typically 1 mL for SPE and 10 μL for MEPS. MEPS can handle both small 
and large volumes (from 10 μL up to 1000 μL) and is suitable for normal phases, reversed 
phase, mixed mode and ion exchangers.  This approach is much less expensive than SPE 
because the MEPS syringe can be used several times, up to 100 times or more, while 
Figure 23 - MEPS structure. Image adapted from SGE Analytical Science and Metrolab [95, 96]. 
 
conventional SPE columns and cartridges are used only once. Moreover, MEPS can be fully 
automated, taking only about one minute to process each sample. Its utilization prior to LC is an 
excellent tool for screening the presence of drugs and metabolites in blood, plasma, urine and 
saliva samples [94]. Therefore, MEPS can easily substitute most existing methods using SPE 
[93, 95].  
Unlike conventional SPE columns, in MEPS the solid packing material that constitutes the 
sorbent, 1-4 mg, is integrated into a liquid handling syringe (50-1000 μL) barrel. The structure 
of the BIN can be observed in the Figure 23 [95-97]. 
 
 
 
 
 
 
 
 
 
When the sample passes through the solid support, the analytes are adsorbed to the packed 
solid phase. The cartridge is packed to provide selective and suitable sampling conditions. 
According with Pereira et al, MEPS sorbents are generally based in silica particles or polymeric 
phases which are then fine-tuned to obtain different chemical properties and a large portfolio of 
specificities for target analytes [98]. Any sorbent material such silica based (C2, C8, C18); 
strong anion exchange (SAX); strong cation exchanger (SCX) using sulfonic acid bonded silica, 
such as M1 (mix of C8 plus SCX); restricted access material (RAM); carbon; polystyrene-
divinylbenzene copolymer (PS-DVB) or molecular imprinted polymers (MIPs) can be used [93, 
95].  Silica based sorbents have a high retention capability and can cover a wide range of 
interactions, from hydrophobic to hydrophilic (C2 to C18, SAX, SCX, etc.) by the addition of 
different polymers (amines, carboxylic acids, etc.) to silica.  Carbon sorbents have great 
absorption capacity and chemical, thermal and mechanical resistance. Polymerics sorbents (PS-
DVB) are robust have higher surface contact areas, are suitable for extractions all over the entire 
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pH range and work at elevated temperatures and posses improved retention for polar 
compounds as the number of points of interaction between the sorbent and the analyte is 
significantly increased. However, there are also some drawbacks.  Silica based sorbents present 
a narrow pH stability (2 to 7.5), a poor surface contact with aqueous matrices that result in low 
recoveries in extracting polar compounds and the presence of some residual silanol groups. 
Carbon sorbents have a low specific surface area while polymerics sorbents have a lower 
selectivity than the other sorbents [98].   
MEPS technique can be performed manually or can be semi or fully automated by loading 
the Xchange® MEPS syringes in the digital analytical syringe (eVol®) [99, 100]. The Figure 24 
shows the two types of equipments for MEPS technique. This automation brings some 
advantages, such as: less glassware usage; less solvent required; reduces waste fluid; significant 
time saving; improved accuracy and reproducibility; improver operator safety (lower spill and 
splash risk); and complete workflow simplification [99].   
 
The MEPS extraction procedure is normally realized by  essential steps: 1) MEPS 
cartridge condition: wherein there is a passage of an organic solvent followed by; the passage 
of water; 2) Sample loading: corresponds to the passage of the sample a desired number of 
times to retain analytes; 3) Sorbent washing: normally it is used acidified water to remove 
interfering compounds ; 4) Elution: corresponding to the phase where the captured analytes are 
released in a particular solvent, [93, 101].  
Digital analytical syringe eVol® 
Manual MEPS syringes 
Figure 24 – The equipments for MEPS technique. Image adapted from SGE Analytical [98, 99]. 
 
Actually there are countless studies reported using MEPS in different areas of application, 
however, there are not any published articles known about the utilization of MEPS for the 
analytical quantification both Hcys as well as vitamin B cofactors (B6, B9 and B12).  
1.5.2. Ultra-performance liquid chromatography  
Over the past 40 years the practice of chromatography has witnessed a continuous growth in 
almost every respect, since the number of chromatographers, the amount of published work, the 
variety and complexity of samples being separated, separation speed and convenience. Actually 
chromatography is the most versatile and widespread technique employed in modern analytical 
chemistry [102]. 
HPLC is a technique that has arisen from the application to liquid chromatography of 
theories and instrumentation that were originally developed for GC. HPLC has proven to be the 
predominant technology used in laboratories worldwide during the last 30 years, contributing 
for the actually position of chromatography in analytical chemistry world. One of the primary 
drivers for the growth of this technique has been the evolution of packing materials (stationary  
phase) used to effect separation [103].  In the  Figure 25 is possible to look how HPLC works 
[104].  
By the same Figure, HPLC works by the detection of several analytes according with their 
retention time. The sample is injected into a mobile phase that crosses a column (stationary 
phase) made out to interact and trap, for few time, the analytes present in the sample. After the 
column, there is a detector that will identify the compounds according with certain parameters 
(depending on which type of detector is being used), namely the time that the analytes are 
retained since the injection point time (retention time). If an UV-Vis detector is being used, a 
specific wavelength, ideally corresponding to the maximum absorbance of the target analyte(s), 
is used to obtain a chromatogram. Then, the target analytes concentration can be inferred by 
comparison of the respective peak areas in the chromatograms of pure standards and samples. 
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Figure 25 – Schematic diagram of HPLC technique.  Image obtained from Waters [102]. 
 
 
 
For many years, researchers have looked for HPLC as a way to speed up analyses. The need 
for speed has been driven by the sheer numbers of samples in some laboratories and the 
availability of affordable, easy to use mass spectrometers. Smaller columns and faster flow rates 
have been used. Elevated temperatures, having the dual advantages of lowering viscosity, and 
increasing mass transfer by increasing the diffusivity of the analytes, has also been investigated. 
However, using the conventional particles size and pressures, limitations are soon reached and 
compromises must be made, sacrificing resolution for time [105].   
In this way, in early 2004, the first commercially available Ultra Performance Liquid 
Chromatography (UPLC) system that personified these requirements was described for the 
separation of various pharmaceutical related small organic molecules, proteins, and peptides. 
Using UPLC it is now possible to take full advantage of chromatographic principles to run 
separation using shorter columns, and small flow rates for increased speed, with superior 
resolution and sensibility. Faster separation and higher resolution UPLC separation can lead to 
higher throughput and time saving when running multiples samples and can cut method 
development time from days, to hours or even minutes [105].   
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Chapter II: The experimental  
Throughout this chapter it will be described all information concerning to the experimental 
layout of this in this study. 
2.1. Experimental  
2.1.1. Material and reagents  
During this work, all the reagents used were from an analytical purity greater than 95%, not 
being necessary, therefore, any further purification. The Table 2 summarizes all the materials 
and chemicals used for this trial.  
Table 2 – List of chemicals and equipments used throughout this experiment. 
Chemicals Supplier 
Formic Acid (FA) Panreac Química (Barcelona, 
Spain) Sodium Hydroxide (NaOH) 
Acetonitrile (ACN) HPLC degree Fisher Scientific (Lisbon, 
Portugal) Methanol (MetOH) HPLC degree 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
Sigma-Aldrich (St. Louis, MO, 
USA) 
Folic acid  
Pyridoxine  
DL-Homocysteine 
Vitamin B12 
Equipments  
Integral water purification system (18 MΩ cm, 23 ᵒC) 
Milli-Q Millipore Corporation 
(Billerica, MA, USA) 
Polytetrafluoroethylene (PTFE) membrane filters Millipore (Billerica, MA, USA) 
Semi-automated digital analytical syringe eVol® SGE Analytical Science 
(Melbourne, VIC, Australia) MEPS needle and BIN 
Ultra Performance Liquid Chromatography (UPLC) 
Waters (Milford, MA, USA) 
Analytical Column  Waters Acquity UPLC HSS T3 (100 
mm x 2.1 mm, 1.8 μm particle size) 
Acquity UPLC™ HSS T3 Van Guard™ Pre-column 
Expresso Personal Microcentrifuge 
Thermo Fisher Scientific 
(Waltham, MA, USA) 
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2.1.2. Preparation of the standards stock solutions 
A stock solution of DL-Homocysteine (7397 μmol/L or 1 mg/mL) was prepared according 
to Huang et al (2007). Briefly,  10 mg of Hcys powder were dissolved in 10 mL of acidified 
water (0.4% Formic acid) and stored at -20 ºC in 2 mL of aliquots  [106]. As described by 
Valente et al (2012), a stock solution of TCEP (390 mmol/L or 100 mg/mL) was prepared in 
water and stored at -20 ºC [107]. It was also prepared stock solutions of vitamin B6 (5910 
μmol/L or 1 mg/mL) and vitamin B12 (737.8 μmol/L or 1 mg/mL) in water, and vitamin B9 
(2265 μmol/L or 1 mg/mL) in 0.1 mol/L of Sodium hydroxide (NaOH), based on  
Chatzimichalakis et al (2004) [108]. These last stock solutions (vitamin B6, vitamin B9 and 
vitamin B12) were subdivided into 2 mL of aliquots, protected from light and storage at -20ºC. 
2.1.3. Plasma samples 
Validation assays, were performed with five plasma samples from patients with CVD. All 
samples were collected in the laboratory of clinical pathological of the Hospital Dr. Nélio 
Mendonça and stored at -80 ºC until analysis. This study was approved by the ethics committee 
of the Hospital Dr. Nélio Mendonça and all subjects of the study were selected on a voluntary 
way, consenting to participate in the study. The Table 3 summarizes the information (gender 
and age) of the CVD patients group.  
Table 3 – Patients that participate in the study.  
 
Gender Age 
 
 
Patients 
CVD 1 Male 74 
 
CVD 2 Female 75 
CVD 3 Male 63 
CVD 4 Male 67  
CVD 5 Male 66  
 
2.1.4. Chromatographic conditions 
The method for the simultaneous quantification of Hcys and vitamins B was carried out on 
a Waters Ultra Performance Liquid Chromatographic Acquity system (UPLC, Acquity H-Class) 
equipped with a quaternary solvent manager (QSM), a sample manager (SM), a strength silica 
HSS T3 analytical column (100 mm x 2.1 mm, 1.8 μm particle size) protected with a HSS T3 
Van Guard™ Pre-column Acquity, a column heater and a PDA detector. The whole 
configuration was driven by Empower software v2.0 from Waters Corporation.  
Several gradients with different mobile phases combinations were performed (Annex I) in 
an attempt to combine all analytes in a same chromatographic methodology.  
From all the set of gradients mobile phase programs tested (Annex I), two gradients, one for 
Hcys and other for vitamins, provided an optimal separation. All sorbents and samples were 
filtered through 0.22 μm PTFE filters, before use. 
The separation for Hcys and vitamins cofactors occurred with a constant flow rate of 200 
μL min-1, giving a maximum back pressure of 6000 psi, which is within the capabilities of the 
UPLC™. The column temperature was thermostated at 30ºC and the samples were kept at 23 ºC 
in the sample manager. The analysis was performed during 5 min followed by a re-equilibration 
time of 2 minutes. Beyond the difference in the gradients, different volumes of injection were 
used 2μL and 5 μL for Hcys and vitamins assays, respectively. 
For quantification purposes the PDA detection was set with four distinct channels 
corresponding to the maximum absorbance wavelength of each analyte (Hcys: 280 nm; Vitamin 
B6: 290 nm; Vitamin B9: 284 nm; Vitamin B12: 360 nm). The analytes were identified by 
comparing the retention time and spectral characteristics of their peaks.  
 
2.1.5. Method for the extraction of Hcys and vitamins  B 
2.1.5.1.  MEPS extraction and optimization 
For a proper extraction prior to the chromatographic separation of Hcys and vitamins, two 
different MEPS procedures were performed. The Table 4 summarizes this two extraction 
techniques performed along with the optimization conditions also performed in this study. The 
method A corresponds to the MEPS extraction of Hcys and the method B corresponds to the 
MEPS extraction of vitamins. 
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Table 4 – MEPS extraction procedures for Hcys and vitamins.  
 Optimization 
conditions 
A (Hcys)  
B(Vitamins) 
MEPS steps Sorbents 
C2, C8, C18, SIL, M1, DVB, HLB DVB, R-AX, R-CX, PGC, 
PEP and C18(Thermo) 
Cartridge 
condition 
 
250 μL of ACN 
250 μL of 0.01%F A 
250 μL of MetOH 
250 μL of 0.05% FA 
Sample loading 
Number of  sample 
cycles 
Standards/plasma containing 20 
μL of TCEP (390 mmol/L) 
C1: 200 μL 
C2: 2 x 100 μL 
C3: 4 x 50 μL 
Standard/plasma 
C1: 200 μL 
C2: 2 x 100 μL 
C3: 4 x 50 μL 
Sorbent 
washing 
Washing volume 
0.01% FA 
C4: 250 μL 
C5: 100μL 
0.05 % FA 
C4: 250 μL 
C5: 100 μL 
Elution 
Solvent organic  
percentage 
ACN/0.01% FA 
C6: 60% 
C7: 80% 
C8: 90% 
MetOH/0.05% FA 
C6: 60% 
C7: 80% 
C8: 90% 
 
The standard solutions used for the experiments were prepared from the initial stock 
solutions refereed at the subtopic 2.1.2, by diluting in acidified water (0.05% FA). However, for 
the method A the dilution was performed in 0.05%AF containing 10% of TCEP (7.8 mmol/L). 
It was used for the method A, 25 ng/μL (184 μmol/L) of Hcys as standard solution, and for the 
method B, 0.4 ng/μL of each vitamin (vitamin B6: 1.6 μmol/L; B9: 100 nmol/L and B12: 296 
nmol/L). 
The plasma samples were previously filtrated with 0.2µm PTFE. For the method A, before 
the plasma filtration it was added to a certain volume of plasma 10 % of TCEP.  To optimize the 
Figure 26 – MEPS recovery points for the optimization. 
 
two techniques, several recovery points (after sample loading; after washing, and elution) were 
collected to evaluate the best conditions for the extraction. Through the collecting of these 
recovery points it is possible to evaluate if there is retention of the analyte by the sorbent and/or 
undesired loss of analyte between the steps until the elution. The Figure 26 shows this recovery 
points.  
 
 
 
 
 
 
 
The optimization of the best fibre, best number of sample cycles (C1 C2 and C3), the 
volume of washing (C4 and C5) and the elution (C6, C7 and C8) were evaluated by collecting 
the recovery points referred previously. For the best sorbent, the best number of sample cycles 
and for the best volume of washing, it was used the elution condition C7 (80% ACN/0.01% FA 
for Hcys and 80% MetOH/0.05% FA for Vitamins B). The evaluation of the best condition was 
based on the comparison of the average peak area of each analyte. For the method B, however, 
as it was used for the simultaneous extraction of vitamins, the best condition was chosen among 
the better condition for the three vitamins.  
2.1.5.2. Protein precipitation for Hcys extraction 
The evaluation of the extraction of Hcys by  protein precipitation (PP) was performed as 
described by Persichilli et al (2010) [88]. First, 200 μL of plasma were submitted to the 
reduction with 20 μL of TCEP (390 mmol/L), to break the sulphur bonds of Hcys; then 200 μL 
of MetOH were added to precipitate the proteins. This mixture centrifuged at 10.000 during 5 
minutes.  Finally, 200 μL of supernatant was collected and injected (2 μL of the 200 μL) into the 
UPLC system. This same procedure was also performed with the calibrations solutions used for 
the validation of the method.  
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2.2. Validation of the analytical methods 
For the validation of the methods, several calibration solutions were prepared The range of 
concentrations used for each biomarker, were selected according with sensibility of UPLC-PDA 
and the normal plasma range levels of each compound.  The Table 5 summarizes all range of 
concentrations used as calibration solutions of Hcys, vitamin B6, vitamin B9 and vitamin B12. 
Table 5 – Calibration solutions used for the validation of Hcys and vitamins B. 
Compound 
Concentration 
(μmol/L) 
Amount  
 (ng) 
Hcys 
4 0.5 
7 1 
30 4 
184 25 
370 50 
555 75 
Vitamin B6 
0.030 7.4 x 10
-3
 
0.300 7.4 x 10
-2
 
1.6 0.4 
6.5 1.6 
300 74 
3000 740 
Vitamin B9 
0.010 4 x 10
-3
 
0.100 0.4 
0.400 1.6 
1 4 
10 40 
200 800 
Vitamin B12 
7.4 x 10 
-5
 1 x 10 
-4
 
7.4 x 10 
-4
 1 x 10 
-3
 
0.296 0.4  
1 1.6 
7.40 10 
74 100 
 
The methods performed were submitted to the same validation parameters. Selectivity, 
linearity, limit of detection (LOD), limit of quantification (LOQ), precision inter- and intra-day, 
recovery (accuracy) and matrix effect were therefore assessed. These parameters were 
calculated for each analyte using concentrations usually found in human plasma.  
The selectivity was evaluated by the absence of interfering compounds on the retention time 
of the analytes, in plasma samples analysis by UPLC-PDA.  
The linearity was estimated through the determination of the correlation coefficient. Three 
calibration curves for each analyte were performed, with six different concentrations prepared in 
acidified water (0.05% FA). Each concentration was injected thrice. The calibration curve was 
calculated by the graphical representation of a set of different media of peak areas 
corresponding to different concentrations of the analytes [109].   
The sensibility of the methods was evaluated by the LOD and the LOQ for each compound. 
The LOD and LOQ were calculated through the lowest concentration level of the analyte in the 
linearity evaluation. LOD was obtained by 3 x standard deviation (SD) and LOQ was calculated 
by 10 x SD [109].  
The precision, expressed by the percentage of relative standard deviation (RSD), was 
evaluated by the injection of three concentration levels of the analytes, corresponding to low 
level (LL), medium level (ML) and high level (HL) from the calibration curve. It were analysed 
six replicas (n=6) at the same day, in order to obtain repeatability (precision intra-day).  For the 
reproducibility (precision inter-day), it were analysed six replicas for each level of concentration 
during three non-consecutive days (n=18) [109].   
The recovery of the method, performed to both methods, was estimated by the recovery 
percentage of the different analytes through the extraction procedures previous discussed. This 
evaluation was performed using three levels of concentrations, LL, ML and HL. Recovery was 
calculated according with the following equation: recovery percentage = 100 x (concentration of 
the fortified standard – concentration of the standard)/ added analyte concentration [109].  
The matrix effect was evaluated by the percentage of the quotient between the slopes of the 
standards in blank matrix (acidified water for Hcys method and 80% or 90% of acidified 
methanol for vitamins method) and those obtained by fortified plasma (standard addition 
method) [110].  
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A 
B 
1 2 3 
4 
 
Figure 27 – Chromatographic separation of Hcys and vitamins B. Legend: A| Gradient mobile phase scheme. B| 
Chromatograms. The black chromatogram correspond to the max wavelength of 238 nm; the blue to the max wavelength of 290 nm; 
the green to the max wavelength of 260 nm; 1| peak of Hcys + interfering compound; 2| peak of vitamin B6; 3| peak of vitamin B12; 4| 
peak of vitamin B9. 
 
Chapter III: Results and Discussion  
Throughout this chapter, the data obtained in this work will be presented, interpreted and 
discussed. The steps used in the developing of the methodology for the determination of the 
Hcys and vitamins B, the optimization of the processes and the validation of the procedures, 
will be discussed and compared with published work whenever possible.    
3.1. A unique methodology for Hcys and vitamins B chromatographic 
separation 
After optimizing the extraction technique for plasma samples, several gradients were used 
in an attempt to combine all the analytes in a single chromatographic methodology. In Figure 
27A and 27B, are shown the gradient that allowed the best separation and the respective 
chromatogram. The remaining gradients tested in this work are indicated in the Annex I.   
 
 
 
 
 
 
 
As Figure 27B shows, the gradients tested did not allowed the simultaneously quantification 
of the four analytes on the available columns as Hcys and vitamin B6 separation was not fully 
achieved and moreover, there is a non-identified interferents coeluting with Hcys. The difficulty 
to find optimum conditions for target compounds involves a number of reasons. The selected 
analytes have acid dissociation constant (pKa) values very different (2.46, 9.41 and 10.28 to 
Hcys [111]; 5.58, 9.40, 14.53 and 15.20  to vitamin B6 [112];  3.37, 4.17, 7.61, 7.61, and 18.09 
to vitamin B9 [113]; and 8 successive pKa for B12, ranging from 0.53 to 12.59 [114], as 
indicated in Annex II), our column has a limited range of pH (2-8), and the use of TCEP (which 
is acidic) was necessary to maintain the Hcys stable (at physiological pH (pH=7) it tends to 
form dimmers [55]). Associated to this, compounds with lower pKa values elute faster, whereas 
compounds with higher pKa values tend to elute slower at lower pH because higher ionization 
tends to occur at lower pH [86]. Therefore, there were too many factors playing a crucial role 
for an optimal separation of the selected analytes and it was not possible to optimize them in 
order to be possible the chromatographic separation in the UPLC system and conditions 
available.   
Although my best efforts by the use of several of gradients with different profiles, solvents 
constitutions, percentages and pH, in order to solve the problems refereed above, I was not 
succeeded in obtain Hcys and vitamins B-cofactors simultaneous quantification. In this sense, 
particularly Hcys quantification followed a different methodology than what was the initial 
objective of the study. Nevertheless, this new method sought accomplishes with the aim of the 
study in getting a simple, fast, cheaper and reliable method for the clinical quantification of 
Hcys. To achieve this, Hcys and vitamins B quantification and MEPS extraction were assayed 
using the same conditions previously reported at the experimental section. 
3.2. Identification and quantification of Hcys  
3.2.1. Chromatographic separation  
As referred previously, the impossibility to resolve Hcys and vitamins B in a single 
chromatographic run, lead us to developing separated method for Hcys and vitamins B (B6, B9 
and B12) that accomplishes with the aims of the study.  
From the set of different gradients previously tested (Fig. 28 and Annex I), the best gradient 
was selected and further optimized for the optimal separation of Hcys. This optimization 
involved column temperature and flow rate adjustments. Table 6 shows the optimal 
chromatographic conditions for Hcys separation.  
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Table 6 – Optimal chromatographic conditions for quantify the Hcys. 
Chromatographic 
parameters 
Optimal Chromatographic conditions 
 
 
Column 
Analytical Column  Waters Acquity UPLC HSS 
T3 (100 mm x 2.1 mm, 1.8 μm particle size)  
Gradient mobile 
phase program 
Time (min) 
0.1% FA ACN/ 0.1%  FA 
 0 95 5 
0.5-1.5 100 0 
2 95 5 
 3 80 20 
4-5 95 5 
Flow rate 200 mL min 
-1
 
 
Column 
temperature 
30 ºC  
Injected volume 2 μL 
 
UV detection 
wavelenght  
280 nm  
Time of retention  1.25 min 
 
 
3.2.2. Methods for extracting Hcys 
As referred in the experimental section (subtopic 2.5 of the chapter II), two extraction 
procedures were performed:  1) extraction by MEPS and 2) extraction by PP.  
 3.2.2.1. Extraction by MEPS 
In order to improve the efficiency of Hcys MEPS extraction from plasma samples, the 
sorbents were optimized in the first place. For this evaluation, volumes in the crucial steps of 
the MEPS methodology identified in the experimental section as recovery points (Figure 26) 
were collected. The conditions assayed, C1, C4, and C7, are described in the Table 4. The 
Figure 28 shows the average peak area of Hcys obtained from each recovery point per sorbent 
and the direct injection of Hcys (25 ng per volume injected, corresponding to the same amount 
of Hcys in volume of standard solution loaded).   
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Figure 28 – Influence of sorbents on extraction efficiency of Hcys.  
 
 
According to this figure, it is possible to note that all the sorbents had low levels of 
retention at the sample loading step. The values of recovery of all the sorbents ranged from 2 up 
to 10 % (Table 7). Even the very low amounts retained are mostly washed away in the washing 
step. This situation is clearly observed in the M1 fibre, which although presents the higher Hcys 
retention (10.59%), the analyte is lost during wash and nothing is recovered in the elution step. 
In opposition, there is only a very residual retention of Hcys in the PGC and PEP fibres (5.72% 
and 2.45%, respectively; Table 7) that is not lost during the wash step, being eluted in the final 
MEPS extraction step. Nevertheless, M1 was selected as the best sorbent for the next 
optimization steps due to its higher retention abilities for Hcys.  
Table 7 –Influence of sorbents on the extraction efficiency of Hcys. 
Sorbents Recovery % 
SIL - 
C2 2.18 
C8 4.23 
M1 10.59 
C18 6.37 
C18 (Thermo) 9.03 
R-AX 3.87 
R-CX - 
PGC 5.72 
PEP 2.45 
DVB 3.81 
HLB DVB 7.04 
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of the 
progression of cardiovascular disease 
2013 
 
 
57 
 
Figure 29 – Influence of number of cycles on extraction efficiency of Hcys.  
  
 The number of sample loading cycles was then performed. To do that, C1 (1x 200 μL), C2 
(2 x 100 μL) and C3 (4 x 50 μL) conditions were evaluated and compared. The Figure 29 shows 
the average peak area of Hcys obtained from each recovery point per each condition.  
According with the same figure, it was not possible to obtain a better extraction efficiency 
of Hcys. By contrast, it was noted that with the increase of number of cycles less Hcys were 
retained. This was also confirmed by the recovery rates (10.59 % for C1, 5.13% for C2 and 
2.38% for C3).   
 
The imperative of using a lower pH (3-4) to maintain the Hcys stabilized, results in a lower 
intermolecular interaction between the analytes and the compounds that constitute the sorbent, 
favouring the sorption of them [115]. This is most likely the main reason for the low recovery 
rates of Hcys and for the difficulty in improving its efficiency of extraction. In the annex II it is 
possible to see the most probably form of Hcys at the pH of 3-4.  
Several others methods were adapted from SPE descriptions (Annex III) and used in an 
attempt to retain the Hcys on MEPS sorbents, at least with the same efficiency than the method 
here described. Nevertheless, attempts provide better results than the ones described. 
 
 
 
 
Figure 30 – Chromatogram of Hcys extraction by protein precipitation of plasma. Legend: 1| peak area of 12±2.4 μmol/L of 
Hcys. The Hcys concentration was calculated by the equation of the line of the calibration curve. 
 
λmax: 238 nm 
3.2.2.2. Extraction by PP 
Plasma PP was performed as described in the experimental section as an alternative to 
MEPS extraction. The Figure 30 shows a chromatogram of Hcys obtained from the use of 
protein precipitation in plasma samples.  
 To evaluate the extraction efficiency of Hcys by this method, it was performed a simulation 
of plasma PP. For this, it was substituted plasma for 200 μL of acidified water (0.05% FA) 
containing a known concentration of Hcys (25 ng/μL) and compared the peak area of Hcys 
obtained of from it with other peak are of Hcys obtained from a direct injection without PP. It 
was also performed a blank assay without Hcys.  
The extraction efficiency of Hcys through PP (88.6%) was much higher than the obtained 
by MEPS.  
3.2.2.3. Using MEPS and PP to improve Hcys quantification 
According with results reported previously, PP is most efficiency to extract Hcys than 
MEPS. However, as it is possible to see at the Figure 30, there are some interfering compounds 
near the peak of Hcys that it would be interesting to improve.  
In this way, MEPS was used following PP to try to cleanup samples from the interfering 
compound. In this way, after performing the PP of a fortified plasma sample (25 ng of Hcys), 
the supernatant (200 μL) was submitted to MEPS. C2 was the select sorbent, as it was the 
sorbent with less recovery rate (Table 7). The recovery point after sample loading was collected 
to compare with a sample from the same aliquot submitted only to PP.  
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Figure 31 – Influence of MEPS on the extraction efficiency of Hcys by PP. Legend: PP| Plasma sample submitted only to protein 
precipitation; PP+MEPS| Plasma samples submitted to protein precipitation and MEPS. 
 
 
The Figure 31 shows the average peak area of Hcys from a sample submitted only to PP and 
other that was performed protein precipitation and MEPS as cleanup (PP+MEPS).  
 
 
 
 
 
 
 
 
 
  According with the Figure 31, there is practically no differences regarding average peak 
area of Hcys of a sample submitted to PP and other submitted to PP and MEPS.  
Concerning to interfering compounds near the peak of Hcys, as Figure 32 shows, there are 
almost any difference between the two samples. Therefore, MEPS, as cleanup technique, does 
not improve the chromatographic separation of Hcys and its utilization in Hcys extraction was 
completely discarded both as extraction or cleanup methodologies. 
 
 
 
 
 
Figure 32 – Chromatogram of the influence of MEPS on efficiency of Hcys by protein precipitation. The black chromatogram 
corresponds to the plasma sample submitted only to protein precipitation, and the blue one corresponds to plasma samples submitted to 
protein precipitation and MEPS. Legend: 1| peak area of Hcys obtained from PP; 2| peak area of Hcys obtained from PP followed by 
MEPS. 
1 
2 
λmax: 238 nm 
  
 
 
 
3.2.4. Validation the best method for Hcys assay 
As reported before, PP allowed an extraction of Hcys more efficiently than MEPS and was 
therefore validated for the according with the following parameters:    
a. Selectivity  
The selectivity is an important analytical parameter to ensure that the quantification of the 
analytes of interest are not afected by the presence of interfering compounds in the matrix. For 
the evaluation of this parameter, the chromatogram obtained by a direct injection of the 
standards solution was compared  with the chromatogram obtained by the direct injection of the 
plasma from a patient, verifying the absence of the  interferents on the same time of retention of 
the Hcys. The selectivity was also checked by the resolution of the peak of Hcys in the plasma, 
that revealed  the absence of co-eluting interferents.  
b. Linearity 
Another parameter that was evaluted was the linearity of the method, which can be defined 
as the ability of the method to obtain test results proportional to the concentration of the analyte 
within a given range of concentration [109]. The linearity for Hcys was estimated according to a 
range of concentrations which contains LL, ML and HL of Hcys according with what was 
expected to find in plasma. It was perfomed a calibration curve built by the three replicas of the 
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Figure 34 – Overlap of the chromatograms related to the linearity of the Hcys. Legend: Hcys peak corresponding to: 
1| 7 μmol/L; 2| 30 μmol/L; 3| 184 μmol/L; 4| 370 μmol/L; 5| 555 μmol/L.  
 
λmax: 238 nm 
six calibration solutions (ranging from 4 to 555 μmol/L, as indicated in Table 5)  prepared in 
acidified water (0.05% FA).  The Figure 33 shows the calibration curve for Hcys and the Figure 
34 shows the overlap of different chromatograms from each concentration used for the 
evaluation of linearity.  
 
Figure 33 – Calibration curve of Hcys. 
 
 
c. LOD and LOQ 
The LOD and the LOQ were calculated  by the lowest concentration of the analyte detected 
by UPLC. For LOD this value should be reliably distinguished from zero or be 
detected/measured with reasonable statistical certain. LOD should be three times higher than the 
noise level, being therefore calculated by 3 x SD. For LOQ this value should be determined 
quantitatively with an acceptable level of repeatability, precision and trueness, and should be ten 
y = 73,047x + 92,194 
R² = 0,9968 
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times higher than the nose level, being in this way, calculated by 10 x SD of the lowest 
concentration [109]. 
For Hcys , LOD and LOQ were calculated based on the lowest concentration used for the 
linearty, 4 μmol/L. The Table 8 presents the LOD and LOQ obtained for Hcys as well as the 
values obtained from other similar study  that use the same equipment (UPLC and UV detector). 
Table 8 – Comparison of the LOD and LOQ obtained with other study. 
 
Studies 
 
 
LOD 
(μmol/L) 
 
 
LOQ 
(μmol/L) 
Hcys 
Our study  0.07  0.21 
Valente et al [107]  0.05  0.15 
 
According with Nekrassova et al (2003), the values of LOD and LOQ obtained in this 
studies are lower than the most of the common chromatographic techniques,  used for quantify 
Hcys which do not use MS, and unlike this study, most of them require laborious samples pre-
treatments and complex gradient programs with high column temperatures and longer 
chromatographic separations [55].  
Valente et al (2012) obtained a much higher analytical performance than the one here 
developed, with LODs and LOQs at least five times lower than the reported limits in the 
literature. However, unlike this study, their method uses derivatizing agentes (SDB-F and ABD-
F) that need at least 40 min to react with thiol groups, a mobile-phase composition based on 
phosphate buffer (30-100mM) and a chromatographic run of 10 min  (Hcys retention time of 8.5 
min) [107].    
d. Precision 
The precision for the method here presented, expressed by the RSD, was evaluated by the 
injection of three concentration levels corresponding to 7μmol/L to LL, 184 μmol/L to  ML and  
555 μmol/L HL. To obtain the repeatability (precision intra-day), it was injected six replicas of 
each concentration (n=6). For the evaluation of reproducibility (precision inter-day), it were 
injected six replicas of each concentration during three non-consecutive days (n=18). The Table 
9 presents the RSD values of each concentration for the  precision intra-days and inter-days.  
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Table 9 –Intra-day and inter-day precision. 
 
Levels of 
concentration 
 
 
RSD 
(%) 
 
 
Intra-day 
(n=6) 
LL  3.32 
 
ML  1.23 
HL  1.31  
 LL  6.15  
Inter-day 
(n=18) 
ML  6.99  
 
 
HL  5.43 
 
 
According with United Nations Office on Drugs and Crime,  this value should be better than 
20% at lower concentrations and better than 15% at higher concentrations [116]. In this sense, 
the results obtained in this study do not fulfil this criteria for the validation of analytical 
methodologies, as all the RSD values obtained are bellow than 15%. The precision intra-day 
ranged from 1.31 to 3.32 %, whereas the precision inter-day ranged from 5.43% to 6.99%.  
e. Recovery 
This evaluation was performed by the use of three levels of different concentrations, 7 
μmol/L (LL), 184 μmol/L (ML) and 555 μmol/L (HL). The values of recovery percentage were 
calculated according with the following equation: recovery percentage = 100 x (concentration of 
the fortified standard – concentration of the standard)/ added analyte concentration.  
The Table 10 shows the recovery values of the three levels of concentration. 
 
 
 
 
Table 10 – Values of recovery. 
Concentration Recovery (%) 
7 μmol/L 93.1 
184 μmol/L 88.5 
555 μmol/L 82.5 
 
f.  Matrix effect 
The matrix  effect was estimated by the percentage of the quotient between the slopes of the 
standard in blank and the obtained by fortified plasma, through the use of three Hcys levels of 
concentration, 7 μmol/L (LL), 184 μmol/L (ML) and 555 μmol/L (HL). The three levels of 
concentration were added to the plasma by the standard addition method.  
According Figure 35, it is possible to observe that there is a matrix effect for Hcys (>120 
%). The value of matrix effect was estimated by the percentage of the quotient between the 
slopes of the standards in blank matrix and those obtained by fortified plasma. 
 
Figure 35 – Matrix effect of the plasma on the Hcys. 
 
3.2.4. Clinical application of the methodology for Hcys quantification  
After the validation of the methodology to quantify Hcys, five plasma of patients with CVD 
were quantified. The table 11 summarizes the results for Hcys concentration in each sample.  
y = 125,348386x + 424,478132 
R² = 0,999999 
y = 74,812053x + 136,126223 
R² = 0,999954 
0 
10000 
20000 
30000 
40000 
50000 
60000 
70000 
80000 
0 100 200 300 400 500 
A
v
er
a
g
e 
p
ea
k
 a
re
a
 o
f 
H
cy
s 
Concentration (μmol/L) 
Matrix effect of the plasma on the Hcys 
Plasma Standard 
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of the 
progression of cardiovascular disease 
2013 
 
 
65 
 
Table 11 – Values of the clinical application of the method for quantify the Hcys. 
Hcys 
 
Measure Mean  + RSD 
(μmol/L) 
 
 
Samples 
CVD 1 4.3 ± 1.2 
 
CVD 2 0.4 ± 0.2 
CVD 3 13.8 ± 4.1 
CVD 4 23 ± 4.6  
CVD 5 4.6 ±0.9  
 
From our results, only two patients had Hcys levels higher than normal (5-10 μmol/L), but 
only one had a level that is considered as HHcys (23 ± 4.6 μmol/L) However, due to the sample 
size, and the lack of information of the clinical situtation of the patients it is not possible to 
make any conclusion in relation to high levels of homocysteine and CVDs. This clinical 
application of the method serves only to demonstrate the feasibility of this method in the Hcys 
quantification.  
3.3.  Identification and quantification of vitamins B 
3.3.1. Chromatographic separation 
As already discussed, a different methodology from the one used in Hcys, have been 
adopted to identify and quantify the three vitamins B. After various optimizations of gradient 
programs (Annex I), columm types (T3 HSS and BEH C18) and column temperatures, it was 
found an optimal condition to separate all the three vitamins in the same chromatographic 
method. The table 12 summarizes all the parameters that have contributed for a sucessful 
chromatographic separation of the standards containing the three vitamins. This search for best 
chromatographic method involved the direct injection of the standard solutions containing all 
the vitamins, leaving the optimization of the extractive technique for the following steps.  
 
 
 
Table 12 – Optimal chromatographic conditions for quantify the vitamins B-cofactors. 
Chromatographic 
parameters 
Optimal Chromatographic conditions 
 
 
Column 
Analytical Column  Waters Acquity UPLC HSS T3 
(100 mm x 2.1 mm, 1.8 μm particle size) 
 
Gradient mobile 
phase program 
Time (min) 0.05% FA Methanol 
 0-0.5 80 20 
1 40 60 
1.5-2 80 20 
 3 70 30 
4-5 80 20 
Flow rate 200 mL min 
-1  
Column 
temperature 
30 ºC  
Injected volume 5 μL  
UV detection 
wavelenght  
Vitamin B6 290 nm 
 
Vitamin B9 284 nm 
 
Vitamin B12 360 nm 
 
Time of retention 
Vitamin B6 1.2 min 
 
Vitamin B9 3.8 min 
 
Vitamin B12 3.5 min 
 
 
The Figure 36, shows the chromatogram of the best chromatographic contition obtain from 
the direct injection of the standard solutions of the three vitamins B.  
 
Figure 36 - Chromatograms of vitamins B standards obtained by the optimal chromatographic condition. Legend: Peak 
identification: Vitamin B6: 1| 6.5 μmol/L (1.6 ng/μL) and 2| 13 μmol/L (3.2 ng/μL); Vitamin B12:  3| 1 μmol/L (1.6 ng/μL) and 4| 
2 μmol/L (3.2 ng/μL); Vitamin B9:  5| 0.400 μmol/L (1.6 ng/μL) and 6| 0.800 μmol/L (3.2 ng/μL). 
λmax: 
290 nm 
λmax: 360 nm 
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Influence of sorbents on extraction efficiency of vitamins B 
VIT B6 VIT B9 VIT B12 
Vitamins exist in vestigial levels in biological matrix, so it was necessary an extraction 
technique to separate and concentrate them, bellow the sensitivity levels of the equipment.   
 
3.3.2. Optimization the MEPS for extracting the vitamins B6, B9 and B12 
The optimization of the vitamins extraction using MEPS followed the layout defined in the 
Table 4. Accordingly, the optimization began with the selection of the best sorbent, followed by 
optimization of the number of sample loading cycles, the volume of washing, and  the 
percentage of organic solvent of the elution solution.  This optimization involved the collection 
of the recovery points after loading sample, after washing and elution, as previously defined and 
illustrated in the Figure 26. 
For all the optimization procedures, the sorbent was loaded with 320 ng from each vitamin 
B in 200 μL of acidified water (0.05% FA). In the literature is reported the fortification of 40 μL 
of plasma for SPE extraction [108]. In this work, we preferred to use a higher sample volume 
(200 μL) in order to obtain higher detection sensitivity, as vitamins B are at vestigial levels in 
plasma.   
a.  Selection of the best fibre 
For selecting the best sorbent, which has more analytes retained, it was evaluated twelve 
sorbents, SIL, C2, C8, M1, C18, C18 Thermo, R-AX, R-CX, PGC, PEP, DVB and HLB DVB, 
using, the C4, C7 conditions described in Table 4 (briefly, 200 μL of sample loading, 250 μL 
0.05% FA as the washing volume and elution with 80% MetOH/0.05%FA). The elution 
recovery point of each sorbent was used for the analysis of the peak area of vitamins, in order to 
compare all the sorbents, as shown in Figure 37.  
Figure 37 – Comparison of the influence of MEPS sorbents and direct injection on the extraction efficiency of vitamins B. 
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Influence of number of loading cycles on extraction efficiency of 
vitamins B 
Vit B6 Vit B9 Vit B12 
According with Figure 37, it is possible to note that M1 is the best sorbent for the 
simultaneous extraction of the three vitamins. A direct injection of a standard solution 
containing 8 ng of each vitamin was used as control (equivalent to a value of 100% of recovery 
of the analytes upon the MEPS extraction).   
b. Optimization of the number of loading cycles  
After the selection of the best fibre, M1, it was evaluated the optimal number of sample 
loading cycles in this sorbent. In this way, it was performed the evaluation the conditions of 
number of loading cycles in order to select the best cycle for a better retention of all analytes: 
C1 (1 X 200 μL); C2 (2 x 100 μL) and C3 (4 x 50 μL). 
For this evaluation, it was used a standard solution containing 320 ng/ 200μL, and it was 
collected the recovery points, after loading and elution (80%MetOH/0.05%FA) of each sample 
loading condition. C1, C2 and C3 indicated in Table 4 (respectively 1 x 200 μL, 2 x 100 μL and 
4 x 50 μL), using 320 ng of each vitamin / assay, and it were collected the recovery points, after 
loading and elution (condition C7 for elution: 80%MetOH/0.05%FA) of each sample loading 
condition. The washing condition used for this evaluation was the condition C4 (250 μL of 
0.05% FA). 
The Figure 38 shows the average peak area of vitamins B in each recovery point.   
 Figure 38 – Influence of number of loading cycles on extraction efficiency of vitamins B. 
VIT B6 VIT B9 VIT B12 
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According with this figure it is possible to note that the best cycle corresponds to four 
sample loading cycles of 50 μL each one (C3 condition), being the condition that presents 
cumulatively the higher extraction efficiency for the three vitamins analysed. 
c. Optimization of the washing volume  
The next step of the MEPS optimization was the washing volume (conditions C4 and C5, 
100μL or 250 μL of acidified water, respectively, see Table 4 for details). Both the rejected 
volume after each washing step and the correspondent elution phase (C7 condition: 80% 
MetOH/0.05%FA) were collected for comparison. For the evaluation of this procedure it was 
used the number of cycles previously optimized and a standard solution with the same 
concentration of vitamins B. Figure 39 shows the washing effect in the vitamins retention. As 
can be depicted from the figure, a higher washing volume corresponds to a higher loss of the 
target analytes (condition C4).     
 
Figure 39 – Influence of washing volume on the extraction efficiency of vitamins B. 
According the previous graphic, it is possible to note that the best washing volume was 100 
μL (C5), as it presents less loss of vitamins at the washing step and more vitamins at the 
correspondent elution phase.  
.  
 
0 
50000 
100000 
150000 
200000 
250000 
Washing after 
loading 
Elution Washing after 
loading 
Elution 
C4 (250 μL)  C5 (100 μL) 
A
v
er
a
g
e 
p
ea
k
 a
re
a
 o
f 
v
it
a
m
in
s 
B
 Vit B6 Vit B9 Vit B12 
Influence of washing volume on extraction efficiency of vitamins B 
VIT B6 VIT B9 VIT B12
0 
50000 
100000 
150000 
200000 
250000 
Elution C6 (60% 
MetOH/0.05%FA) 
Elution C7 (80% 
MetOH/0.05%FA) 
Elution C6 (90% 
MetOH/0.05%FA) 
A
v
er
a
g
e 
p
ea
k
 a
re
a
 o
f 
v
it
a
m
in
s 
B
 
Vit B6 Vit B9 Vit B12 
Influence of elution composition on extraction efficiency of vitamins B 
d. Optimization of the elution system 
At last, once the best washing volume was chosen, the percentage of organic solvent at the 
elution phase was evaluated. Thus, three elution conditions corresponding to 60% (C6), 80% 
(C7) and 90% (C8) of acidified methanol (0.05% FA), were assayed in order to observe which 
one favours a higher recovery of the target analytes retained in the MEPS fibre. The Figure 42 
shows the different elution phases and amount of analytes eluted. 
 
According to Figure 40, it is possible to observe that the best percentage of methanol in the 
elution solution is 80% for all three vitamins B (condition 7).   
3.3.3. Validation of the method for vitamins B 
After the optimization of the MEPS procedure for vitamins extraction, the validation of 
whole analytical methodology using calibrations curves was performed with the vitamins 
solutions indicated in the experimental section (Table 5).   
The selectivity parameter was performed in first place to ensure that the quantification of 
the vitamins B were not afected by the presence of interfering compounds of the matrix. For the 
evaluation of this parameter, the chromatogram obtained in the standards solution MEPS 
extraction was compared with the one  corresponding to a plasma sample and verified the 
inexistence of inferents at the same retention time of each vitamin. . As we can observe in 
Figure 41, there are no interfering compounds at the retention times for the three vitamins B 
analysed. In the same figure, however, we can also depicted that the sensibility of the analytical 
method is very low and it is not yet suitable to  detected the vestigial levels of vitamins usually 
present in plasma samples. In the upper painel of Figure 41, we can observe that the 320 ng of 
Figure 40 – Influence of elution composition system on the extraction efficiency of vitamins B. 
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Figure 41 – Chromatograms of the detection of vitamins B in plasma samples. Legend: The black chromatogram corresponds to 
the plasma sample without fortification and the blue corresponds to the fortified plasma (320 ng/200 μL). 1| peak area of 6.5 μmol/L of 
vitamin B6; 2| peak area of 1 μmol/L of vitamin B12; 3| peak are of 0.4 μmol/L of vitamin B9. 
 
each vitamin B that were used to fortify the 200 μL plasma sample are hardly distinguished 
from the basal line. 
 
 
 
 
 
 
 
 
 
 
 
In the next step, linearity was evaluated for the higher concentration of vitamins solutions 
(Table 5). This parameter was performed to evaluate the viability of this method to extract and 
quantify efficiency vitamins B from other biological samples, once it has not yet the sensibility 
necessary for plasma samples. However, it was not possible to obtain the necessary calibration 
curves as it were obtained uncoherent values due to a non-identified experimental error.   
Unfortunatelly, the time contraints did not allowed to go further in the validation of vitamins B 
quantification using MEPS extraction followed by LC-UV analysis.  This approach has 
potentiality to be suitable for this purpose as Chatzimichalakis et al (2004) succeeded in 
developing a method for quantify vitamins in biological fluids, using SPE as the extraction 
technique, followed by HPLC –UV analysis [108]. Nevertheless, their study worked with higher 
levels of vitamins concentration. Despite their study used only 40 μL of plasma for extraction, 
they spiked the aliquots with 100 μL of water soluble vitamin solutions at concentration levels 
of 1, 2, 5, 10 and 15 ng/μL, injecting 20 μL of the 100 μL of the elution phase.   
 
4.  Conclusion 
The experimental work here described allowed to reach part of the objectives initially 
proposed, while other require more time to be achieved. We had developed a simple, fast and 
cheaper methodology that allows the proper quantification of Hcys in biological samples using 
only 7 min, including the sample process and the chromatographic separation. This method is 
easy and suitable for the clinical environment, just involving a protein precipitation of the 
plasma samples followed by direct injection in the UPLC system and UV detection. This 
methodology is also even faster than initial anticipated because MEPS extraction was shown not 
to be efficient enough in comparison with the protein extraction. Previously, Persichilli et al  
[88] also reported the plasma protein precipitation as extraction procedure for the Hcys 
quantification. Our methodology is, however, simpler, faster and cheaper as it is performed in 
an UPLC and does not involve the expensive MS detection. Unfortunately, it was not possible 
to conjugate Hcys and vitamins B6, B9 and B12 in a single methodology. This was previously 
described [86], but using chromatographic conditions not recommended for the UPLC system 
available, namely buffered gradients. Moreover, we also only have two different 
chromatographic columns available (C18 BEH and HSS – high strenght silica), which clearly 
limit our options to separate such different molecules.  
A separated methodology to quantify vitamins B6, B9 and B12, was therefore developed, 
although not fully validated due to the limited time available to perform this work. Different 
parameters were already optimized, including the MEPS extraction conditions as the best fibre, 
sample volume loading, washing volume and elution solution composition.  
For future perspectives, we suggest the optimization of the method to the clinical 
environment, preferentially combining the four analytes used in this study in a single 
methodology by using new gradients conditions and other chromatographic columns.  
 
 
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of  the 
progression of cardiovascular disease 
2013 
 
5. References 
1.  Celermajer D, Chow C, Marijon E, Anstey N, Woo K. Cardiovascular disease in the 
developing world: prevalences, patterns, and the potential of early disease detection. 
Journal of the  American College of Cardiology 2012 Oct 2;60(14):1207-16. 
2. WHO. Global status report: on noncommunicable diseases. World Health Organization 
2011. 
3. WHO. Global Atlas on cardiovascular disease prevention and control. World Health 
Organization 2011. 
4.  Mathers C, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 
to 2030. Plos Medicine 2006;3(11):2011-30. 
5.  WHF. Cardiovascular disease: Risk factors. Available from: http://www.world-heart-
federation.org/fileadmin/user_upload/documents/Fact_sheets/2012/PressBackgrounderAp
ril2012RiskFactors.pdf. 
6.  Rader D, Daugherty A. Translating molecular discoveries into new therapies for 
atherosclerosis. Nature 2008 Feb 21;451(7181):904-13. 
7.  Born G, Medina R, Shafi S, Cardona-Sanclemente L. Endothelial factors in the flux of 
atherogenic plasma proteins into artery walls. Clinical Hemorheology and 
Microcirculation 2002;26:107-16. 
8.  Pugsley M, Tabrizchi R. The vascular system: An overview of structure and function. 
Journal of Pharmacological and Toxicological Methods 2000;44:333-40. 
9.  Hansson G. Inflammation, Atherosclerosis, and Coronary Artery Disease. The New 
England Journal of Medicine 2005;352(16):1685-95. 
10.  Glass C, Witztum J. Atherosclerosis: The Road Ahead. Cell 2001 Feb 23;104:503-16. 
11.  Vogel R. Coronary Risk Factors, Endothelial Function, and Atherosclerosis: A Review. 
Clinical Cardiology 1997;20:426-32. 
12.  Gallino A, Stuber M, Crea F, Falk E, Corti R, Lekakis J, et al. "In vivo" imaging of 
atherosclerosis. Atherosclerosis 2012 Sep;224(1):25-36. 
13.  Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, et al. From 
endothelial dysfunction to atherosclerosis. Autoimmunity Reviews 2010 Oct;9(12):830-4. 
14.  Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004 
Jun 15;109(23 Suppl 1):III27-32. 
15.  Brevetti G, Schiano V, Chiariello M. Endothelial dysfunction: a key to the 
pathophysiology and natural history of peripheral arterial disease? Atherosclerosis 2008 
Mar;197(1):1-11. 
16.  Andor M. The role of inflammation in endothelial dysfunction and progression of 
atherosclerosis in metabolic syndrome. Timisoara Medical Journal 2005;55(4):330-4. 
17.  Celermajer D. Endothelial dysfunction: Does it matter? Is it reversible? Journal of the 
American College of Cardiology 1997;30(2):325-33. 
18.  Schiffrin E. Remodeling of resistance arteries in essential hypertension and effects of 
antihypertensive treatment. American Journal of Hypertension 2004;17(12):1192-200. 
19.  Belin de Chantemele E, Stepp D. Influence of obesity and metabolic dysfunction on the 
endothelial control in the coronary circulation. Journal of Molecular and Cellular 
Cardiology 2012 Apr;52(4):840-7. 
20.  Hegele R. Plasma lipoproteins: genetic influences and clinical implications. Nature 
Reviews Genetics 2009 Feb;10(2):109-21. 
21.  Saba A, Oridup O. Lipoproteins and Cardiovascular Diseases. In: InTech, editor. 
Lipoproteins - role in health and diseases 2012. p. 197-222. 
22.  Wasan K, Brocks D, Lee S, Sachsbarrable K, Thornton S. Impact of lipoproteins on the 
biological activity and disposition of drugs: implications for drug discovery. Nature 
Reviews Drug Discovery 2008;7:84-99. 
23.  Salway J. Compêndio de bioquímica médica 2006. 
24.  Fogelstrand P, Boren J. Retention of atherogenic lipoproteins in the artery wall and its 
role in atherogenesis. Nutrition, Metabolism & Cardiovascular Diseases 2012 
Jan;22(1):1-7. 
25.  Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G. Association of apo B lipoproteins 
with arterial proteoglycans: Pathological significance and molecular basis. 
Atherosclerosis 1998;139:205-22. 
26.  Badimon L, Vilahur G, Padro T. Lipoproteins, platelets and atherothrombosis. Revista 
Española de Cardiología 2009;62(10):1161-78. 
27.  Niki E. Lipid peroxidation: Physiological levels and dual biological effects. Free Radical 
Biology & Medicine 2009;47(5):469-84. 
28.  Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nature 
Medicine 2011;17(11):1410-22. 
29.  Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clinica Chimica Acta 2010 Dec 
14;411(23-24):1875-82. 
30.  Osterud B, Bjorklid E. Role of Monocystes in Atherogenesis. Physiological Reviews 
2003;83:1069-112. 
31.  Ribeiro F, Alves A, Duarte J, Oliveira J. Is exercise training an effective therapy targeting 
endothelial dysfunction and vascular wall inflammation? International Journal of 
Cardiology 2010 Jun 11;141(3):214-21. 
32.  Maiuri M, Grassia G, Platt A, Carnuccio R, Ialenti A, Maffia P. Macrophage autophagy 
in atherosclerosis. Mediators of Inflammation 2013;2013:584715. 
33.  Hansson G, Libby P. The immune response in atherosclerosis: a double-edged sword. 
Nature Reviews Immunology 2006 Jul;6(7):508-19. 
34.  Fishbein M. The vulnerable and unstable atherosclerotic plaque. Cardiovascular 
Pathology 2010 Jan-Feb;19(1):6-11. 
35.  Plutzky J. Atherosclerotic plaque rupture: Emerging insights and opportunities. The 
American Journal of Cardiology 1999;84(1A):15J-20J. 
36.  Ducros V, Demuth K, Sauvant M, Quillard M, Caussé E, Candito M, et al. Methods for 
homocysteine analysis and biological relevance of the results. Journal of Chromatography 
B 2002;781:207-26. 
37.  Dwivedi M, Tripathi A, Shukla S, Khan S, Chauhan U. Homocysteine and cardiovascular 
disease. Biotechnology and Molecular Biology Review 2011;5(5):101-7. 
38.  Mosharov E, Cranford M, Banerjee R. The Quantitatively important relationship between 
homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and 
its regulation by redox changes. Biochemistry 2000;39(42):13005-11. 
39.  Sharma P, Senthilkumar R, Brahmachari V, Sundaramoorthy E, Mahajan A, Sharma A, et 
al. Mining literature for a comprehensive pathway analysis: a case study for retrieval of 
homocysteine related genes for genetic and epigenetic studies. Lipids in Health and 
Disease 2006;5:1. 
40.  Nygard O, Voliset S, Refusem H, Bratistrom I, Ueland P. Total homocysteine and 
cardiovascular disease. Journal of Internal Medicine 1999;246:425-54. 
41. Royal Society of Chemisty. Chemspider: Homocysteine.  2013; Available from: 
http://www.chemspider.com/Chemical-Structure.757.html?rid=db0ff207-058b-4f97-
8288-50a7f8301394. 
42.  Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. 
Medical Hypotheses 2011 Dec;77(6):1088-93. 
43.  Medina M, Urdiales J, Amores-Sánchez M. Roles of homocysteine in cell metabolism old 
and new functions. European journal of biochemistry 2001;268:3871-82. 
44.  Stein J, McBride P. Hyperhomocysteinemia and atherosclerotic vascular disease. 
Archives of Internal Medicine 1998;158:1301-6. 
45.  Park J, Vollset S, Melse-Boonstra A, Chajes V, Ueland P, Slimani N. Dietary intake and 
biological measurement of folate: a qualitative review of validation studies. Molecular 
Nutrition & Food Research 2013 Apr;57(4):562-81. 
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of the 
progression of cardiovascular disease 
2013 
 
 
75 
 
46.  Nygard O, Refsum H, Ueland P, Vollset S. Major lifestyle determinants of plasma total 
homocysteine distribution: the horland homocysteine study. The American Journal of 
Clinical Nutrition 1998;67:263-70. 
47.  Guldener C. Why is homocysteine elevated in renal failure and what can be expected 
from homocysteine-lowering? Nephrology Dialysis Transplantation 2006 
May;21(5):1161-6. 
48.  Bree A, Verschuren W, Blom H, Kromhout D. Lyfestyle factors and plasma 
homocysteine concentration in a general population sample. American journal of 
Epidemiology 2001;154:150-4. 
49.  Krajinovic M, Lamothe S, Labuda D, Lemieux-Blanchard E, Theoret Y, Moghrabi A, et 
al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute 
lymphoblastic leukemia. Blood 2004 Jan 1;103(1):252-7. 
50.  Cakmak S, Guil U, Kiliç C, Gonul M, Soylu S, Kiliç A. Homocysteine, vitamin B12, and 
folic acid levels in psoriasis patients. Journal of the European Academy of Dermatology 
and Venereology 2009;23(3):300-3. 
51.  Cartarqi B, Parrot-Roulad F, Cochet C, Doucassous D, Roger P, Tabarin A. 
Homocysteine, hypothyroidism, and effect of thyroid hormone replacement. Thyroid 
1999;9(12):1163-6. 
52. Sanchez-Margalet V, Valle M, Ruz F, Gascon F, Mateo J, Goberna R. Elevated plasma 
total homocysteine levels in hyperinsulinemic obese subjects. The Journal of Nutritional 
Biochemistry 2002;13(2):75-9. 
53.  Wollesen F, Bratistrom L, Refsum H, Ueland P, Berglund L, Berne C. Plasma total 
homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. 
Kidney International 1999;55:1028-35. 
54.  Faraci F, Lentz S. Hyperhomocysteinemia, oxidative stress, and cerebral vascular 
dysfunction. Stroke; A Journal of Cerebral Circulation 2004 Feb;35(2):345-7. 
55. Nekrassova O. Analytical determination of homocysteine: a review. Talanta 
2003;60(6):1085-95. 
56.  Jacobsen D. Hyperhomocysteinemia and Oxidative Stress : Time for a Reality Check? 
Arteriosclerosis, Thrombosis, and Vascular Biology 2000;20(5):1182-4. 
57.  McDowell I, Derek L. Homocysteine and endothelial dysfunction: A link with 
cardiovascular disease. The Journal of Nutrition 2000;130:369s-72S. 
58.  Wang H, Tan H, Yang F. Mechanisms in homocysteine-induced vascular disease. Drug 
Discovery Today: Disease Mechanisms 2005;2(1):25-31. 
59.  Fox P, Mazumder B, Ehernwald E, Mukhopadhyay C. Ceruloplasmin and cardiovascular 
disease. Free Radical Biology & Medicine 2000;28(12):1735-44. 
60.  Exner M, Hermann M, Hofbauer R, Hartmann B, Kapiotis S, Gmeiner B. Homocysteine 
promotes the LDL oxidase activity of ceruloplasmin. FEBS Letters 2002;531:402-6. 
61.  Antoniades C, Antonopoulos A, Tousoulis D, Marinou K, Stefanadis C. Homocysteine 
and coronary atherosclerosis: from folate fortification to the recent clinical trials. 
European Heart Journal 2009 Jan;30(1):6-15. 
62.  Au-Yeung K, Woo C, Sung F, Yip J, Siow Y, Karmin O. Hyperhomocysteinemia 
activates nuclear factor-kbB in endothelial cells via oxidative stress. Circulation Research 
2004;94:28-36. 
63.  Jia F, Wu C, Chen Z, Lu G. Atorvastatin inhibits homocysteine-induced endoplasmic 
reticulum stress through activation of AMP-activated protein kinase. Cardiovascular 
Therapeutics 2012 Dec;30(6):317-25. 
64.  Tayal D, Goswami B, Koner B, Mallika V. Role of Homocysteine and Lipoprotein (A) in 
atherosclerosis: An update. Biomedical Research 2011;22(4):391-405. 
65.  Olas B, Kolodziejczyk J, Kedzierska M, Rywaniak J, Wachowicz B. Modification of 
human blood platelet proteins induced by homocysteine and its thiolactone in vitro. 
Thrombosis Research 2009 Dec;124(6):689-94. 
66.  Malinowska J, Tomczynska M, Olas B. Changes of blood platelet adhesion to collagen 
and fibrinogen induced by homocysteine and its thiolactone. Clinical Biochemistry 2012 
Oct;45(15):1225-8. 
67.  Manolescu B, Oprea E, Farcasanu I, Berteanu M, Cercasov C. Homocysteine and vitamin 
therapy in stroke prevention and treatment: a review. Acta Biochimica Polonica 
2010;57(4):467-77. 
68.  Langman L, Cole D. Homocysteine cholesterol of the 90s? Clinica Chimica Acta 
1999;286:63-80. 
69.  Lonn E, Yusuf S, Arnold M, Sheridan P, Pogue J, Micks M, et al. Homocysteine 
lowering with folic acid and B vitamins in vascular disease. . The New England Journal 
of Medicine 2006;354(15):1567-77. 
70.  Toole J, Malinow R, Chambless L, Spence J, Pettigrew C, Howard V, et al. Lowering 
homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial 
infaction and death. JAMA 2004;291(5):565-75. 
71.  Bonna K, Njolstad I, Ueland P, Schirmer H, Tverdal A, Steigne T, et al. Homocysteine 
lowering and cardiovascular events after acute myocardial infarction. The New England 
Journal of Medicine 2006;354(15):1578-88. 
72.  Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of 
lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and 
cause-specific mortality. Archives of Internal Medicine 2010;170(18):1622-31. 
73.  Abraham J, Cho L. The homocysteine hypothesis: still relevant to the prevention and 
treatment of cardiovascular disease? Cleveland Clinic  Journal of Medicine 2010 
Dec;77(12):911-8. 
74.  Malouf R, Grimley E. Vitamin B6 for cognition (Review). Cohrane Database of 
Systematic Reviews 2003(4):1-32. 
75. Royal Society of Chemisty. Chemspider: Pyridoxine 5’-phosphate.  2013; Available 
from: http://www.chemspider.com/Chemical-Structure.1026.html?rid=ca3e3229-afe0-
4cf0-8a26-72fcd4cc07a6. 
76. Royal Society of Chemisty. Chemspider: Pyridoxine.  2013; Available from: 
http://www.chemspider.com/Chemical-Structure.1025.html?rid=3a7f71f0-60d8-4333-
ac23-409f9fa2a6cf. 
77. Stover P. Physiology of Folate and Vitamin B12 in Health and Disease. Nutrition 
Reviews 2004;62(6):3-12. 
78. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease 
processes. Molecular Genetics and Metabolism 2000 Sep-Oct;71(1-2):121-38. 
79. WHO. Serum and red blood cell folate concentrations for assessing folate status in 
population. Vitamin and Mineral Nutrition information System World Health 
Organization 2012. 
80. Melse-Boonstra A, Bree A, Verhoef P, Bjorke-Monsen A, Verschuren W. Dietary 
monoglutamate and polyglutamate folate are associated with plasma folate concentrations 
in dutch men and women aged 20-65 years The Journal of Nutrition 2002;132:1307-12. 
81. Toohey J. Vitamin B12 and methionine synthesis: A critical review. Is nature most 
beautiful cofactor misunderstood? BioFactors 2006;26:45-57. 
82. Royal Society of Chemisty. Chemspider: Cobalamin.  2013; Available from: 
http://www.chemspider.com/Chemical-Structure.4942647.html. 
83. Baik H, Russel R. Vitamin B12 deficiency in the elderly. Annual Review of Nutrition 
1999;19:357-77. 
84. Lawrence J, Roth J. Evolution of coenzyme b12 synthesis among enteric bacteria: 
evidence for loss and reacquisition of a multigene complex. Genetics 1996;142:11-24. 
85. Robert C, Brown D. Vitamin B12 Deficiency. American Academy of Family Physicians 
2003;67(5):979-86. 
86. Shaik M, Gan S. Rapid resolution liquid chromatographty method development and 
validation for simultaneous determination of homocysteine, vitamins b6, b9 and b12 in 
human serum. Indian Journal of Pharmacology 2013;45(2):159-67. 
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of the 
progression of cardiovascular disease 
2013 
 
 
77 
 
87. Nelson B, Satterfield M, Sniegoski L, Welch M. Simultaneous Quantification of 
Homocysteine and Folate in Human Serum or Plasma Using Liquid Chromatography 
Tandem Mass Spectrometry on stable isotope. Analytical Chemistry 2005. 
88.  Persichilli S, Gervasoni J, Iavarone F, Zuppi C, Zappacosta B. A simplified method for 
the determination of total homocysteine in plasma by electrospray tandem mass 
spectrometry. Journal of Separation Science 2010 Oct;33(20):3119-24. 
89.  Lopez-Alarcón M, Chávez-Negrete A, Montalvo-Velarde I, Maldonado-Hernández J, 
Vital-Reyes V. Homocysteine after methionine load in healthy subjects with adequate B-
vitamin status. Cirugía y Cirujanos 2011;79(5):432-8. 
90.  Sadeghian S, Fallahi F, Salarifar M, Davoodi G, Mahmoodian M, Fallah N, et al. 
Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC 
Cardiovascular Disorders 2006;6:38. 
91.  Turqut B, Arlsan S, Demir T, Guler M, Kaya M. Levels of circulating homocysteine, 
vitamin b6, vitamin b12, and folate in different types of open-angle glaucoma. Journal of 
Clinical Interventions in Aging 2010;26(5):133-9. 
92.  Vermaak W, Ubbink J, Barnard H, Potgieter G, Jaarvelds H, Groenewald A. Vitamin B6 
nutrition status and cigarette smoking. The American Journal of Clinical Nutrition 
1990;51:1058-61. 
93.  Abdel-Rehim M. Microextraction by packed sorbent (MEPS): a tutorial. Analytica 
Chimica Acta 2011 Sep 9;701(2):119-28. 
94.  Mandrioli R, Mercolini L, Lateana D, Boncompagni G, Raggi M. Analysis of risperidone 
and 9-hydroxyrisperidone in human plasma, urine and saliva by MEPS-LC-UV. Journal 
of Chromatography B 2011;879(2):167-73. 
95. Abdel-Rehim M. New trend in sample preparation: on-line microextraction in packed 
syringe for liquid and gas chromatography applications. Journal of Chromatography B 
2004;801(2):317-21. 
96. SGE Analytical Science. Microextraction by Packed Sorbent.  2013; Available from: 
http://www.sge.com/uploads/2G/_V/2G_VKvgzgew13fyfOcLiNA/MEPS-
v3_medium.wmv. 
97. Metrolab. Microextraction by Packed Sorbent.  2010; Available from: 
http://www.metrolab.gr/useful_detail_gr.asp?id=10. 
98.  Pereira J, Gonçalves J, Alves V, Câmara J. The microextraction by packed sorbent as an 
effective and high-throughput sample extraction technique. Recent applications and 
future trends. Sample Preparation 2013;1:38-53. 
99. SGE Analytical Science. eVol® XR hand-held automated analytical syringe.  2013; 
Available from: http://www.sge.com/products/evol. 
100. SGE Analytical Science. MEPS syringes 2013; Available from: 
http://www.sge.com/uploads/Dz/sv/DzsvQoEUFy1ra_qxD3OMyw/IM-1051-
S_medium.jpg. 
101. Lafontan M. Advances in adipose tissue metabolism. International Journal of  Obesity 
2008;32 Suppl 7:S39-51. 
102. Snyder L, Kirkland J. Introduction to modern liquid chromatography. Second ed 1979. 
103.  Lindsay S. High Performance Liquid Chromatography 1992. 
104.  Waters. How Does High Performance Liquid Chromatography work?  2013; Available 
from: http://www.waters.com/waters/pt_PT/How-Does-High-Performance-Liquid-
Chromatography-Work%3F/nav.htm?cid=10049055&locale=pt_PT. 
105.  Swartz M. UPLC™: An Introduction and Review. Journal of Liquid Chromatography & 
Related Technologies 2005;28(7-8):1253-63. 
106.  Huang Y, Lu Z, Brown K, Whitehead A, Blair I. Quantification of intracellular 
homocysteine by stable isotope dilution liquid chromatography/tandem mass 
spectrometry. Biomedical Chromatography 2007 Jan;21(1):107-12. 
107.  Valente A, Bronze M, Bicho M, Duarte R, Costa H. Validation and clinical application of 
an UHPLC method for simultaneous analysis of total homocysteine and cysteine in 
human plasma. Journal of Separation Science 2012 Dec;35(24):3427-33. 
108.  Chatzimichalakis P, Samanidou V, Verpoorte R, Papadoyannis I. Development of a 
validated HPLC method for the determination of B-complex vitamins in pharmaceuticals 
and biological fluids after solid phase extraction. Journal of Separation Science 2004 
Oct;27(14):1181-8. 
109.  Taverniers I, De Loose M, Van Bockstaele E. Trends in quality in the analytical 
laboratory. II. Analytical method validation and quality assurance. Trends in Analytical 
Chemistry 2004;23(8):535-52. 
110.  Mendes B, Silva P, Mendonça I, Pereira J, Câmara J. A new and fast methodology to 
assess oxidative damage in cardiovascular diseases risk development through eVol-
MEPS–UHPLC analysis of four urinary biomarkers. Talanta 2013;116:164-72. 
111. Chemicalize. ChemAxon. Homocysteine.  2013; Available from: 
http://www.chemicalize.org/structure/#!mol=C%28CS%29C%28C%28%3DO%29O%29
N&source=fp. 
112. Chemicalize. ChemAxon. Pyridoxine.  2013; Available from: 
http://www.chemicalize.org/structure/#!mol=pyridoxine&source=calculate. 
113. Chemicalize. ChemAxon. Folate.  2013; Available from: 
http://www.chemicalize.org/structure/#!mol=folate&source=calculate. 
114. Chemicalize. ChemAxon. Vitamin B12.  2013; Available from: 
http://www.chemicalize.org/structure/#!mol=vitamin+B12&source=calculate. 
115.  Salami F, Queiroz E. Microextraction in packed sorbent for determination of 
sulfonamides in egg samples by liquid chromatogrpahy and spectrophotometric detection. 
Journal of the Brazilian Chemical Society 2011;22(9):1656-61. 
116.  UNODC. Guidance for the validation of analytical methodology and calibration of 
equipment  used for testing of illict drugs in seized materials and biological specimens. 
United Nations Office on Drugs and Crime 2009. 
  
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of the 
progression of cardiovascular disease 
2013 
 
 
79 
 
6.  Annexes 
6.1. Annex I : Gradient mobile phase programs 
Gradient 1 
Time 
(min) 
MetOH (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 30 ºC 0,5 80 20 
 1 5 95 
 2 80 20 
 3 10 90 
 4 10 90 
 0 59 50 
Gradient 2 
Time 
(min) 
MetOH (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 30 ºC 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
Gradient 3 
Time 
(min) 
MetOH (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 10 90 
Column temperature : 35 ºC 1 5 95 
 2 80 20 
 3 0,6 40 
 4 10 90 
 5 10 90 
Gradient 4 
Time 
(min) 
MetOH (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 35 ºC 0,5 95 5 
 1 95 5 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
Gradient 5 
Time 
(min) 
MetOH (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 35 ºC 0,5 20 80 
 1 40 60 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
 5 20 80 
Gradient 6 
Time 
(min) 
MetOH (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 90 10 
Column temperature : 30 ºC 0,5 95 5 
 1 40 60 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
 5 10 10 
Gradient 7 
Time 
(min) 
MetOH (%) 0.05% FA (%) 
Flow rate 250 μL min.1 0 10 90 
Column temperature : 30 ºC 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
 5 10 90 
Gradient 8 
Time 
(min) 
MetOH (%) 0.05% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 40 ºC 0,25 95 5 
 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
Use of novel biomarkers (homocysteine, vitamin B6, B9 and B12) on the assessing of the 
progression of cardiovascular disease 
2013 
 
 
81 
 
 3 40 60 
 4 20 80 
 5 20 80 
Gradient 9 
Time 
(min) 
MetOH (%) 0.05% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 30 ºC 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
 5 20 80 
Gradient 9 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 30 ºC 0,5 80 20 
 1 5 95 
 2 80 2 
 3 10 90 
 4 50 50 
Gradient 10 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 10 90 
Column temperature : 30 ºC 0,5 80 20 
 1 5 95 
 2 80 20 
 3 10 90 
 4 10 90 
Gradient 11 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 30 ºC 0,5 80 20 
 1 5 95 
 2 80 20 
 3 10 90 
 4 50 50 
Gradient 12 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 30 ºC 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
 3 40 60 
 4 20 80 
 5 50 50 
Gradient 13 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 30 ºC 0,3 5 95 
 0,5 80 20 
 1 5 95 
 1,5 80 20 
 2 80 20 
 3 60 40 
 4 50 50 
 5 50 50 
Gradient 14 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 35 ºC 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
 3 20 80 
 5 50 50 
Gradient 15 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 35 ºC 0,05 95 5 
 0,07 20 80 
 0,1 70 30 
 0,5 20 80 
 1 95 5 
 1,5 20 80 
 2 20 80 
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 3 20 80 
Gradient 16 
Time 
(min) 
MetOH (%) 0.01% FA (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 35 ºC 0,3 5 95 
 0,5 80 20 
 1 5 95 
 1,5 80 20 
 2 80 20 
 3 60 40 
 4 50 50 
 5 50 50 
Gradient 17 
Time 
(min) 
MetOH (%) H20 (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 35 ºC 0,5 20 80 
 5 50 50 
Gradient 18 
Time 
(min) 
MetOH (%) H20 (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 35 ºC 1 50 50 
 2 80 20 
 4 20 80 
 5 20 80 
Gradient 19 
Time 
(min) 
MetOH (%) H20 (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 30 ºC 1 30 70 
 2,5 30 70 
 4 20 80 
 5 20 80 
Gradient 20 
Time 
(min) 
MetOH (%) H20 (%) 
Flow rate 250 μL min.1 0 50 50 
Column temperature : 30 ºC 0,1 10 90 
 0,5 50 50 
 4 50 50 
 5 50 50 
Gradient 20 
Time 
(min) 
MetOH (%) 
0.1% 
FA 
H20 (%) 
Flow rate 250 μL min.1 0 50 0 50 
Column temperature : 30 ºC 1 50 10 40 
 2 80 20 0 
 4 20 20 60 
 5 50 0 50 
Gradient 21 
Time 
(min) 
MetOH (%) 
0.1% 
FA 
H20 (%) 
Flow rate 250 μL min.1 0 50 0 50 
Column temperature : 30 ºC 0,25 20 0 80 
 0,5 80 0 20 
 2 80 10 10 
 5 50 0 50 
Gradient 22 
Time 
(min) 
MetOH (%) 
0.1% 
FA 
H20 (%) 
Flow rate 250 μL min.1 0 50 0 50 
Column temperature : 30 ºC 0,25 0 80 20 
 0,5 0 80 20 
 1 0 5 95 
 1,5 0 80 20 
 2 0 80 20 
 3 0 60 40 
 4 0 80 20 
 4,75 0 80 20 
 5 50 50 50 
Gradient 23 
Time 
(min) 
MetOH (%) 
0.1% 
FA 
ACN (%) 
Flow rate 250 μL min.1 0 20 50 30 
Column temperature : 30 ºC 0,5 20 50 30 
 1 50 50 0 
 2 30 40 20 
 4 20 50 30 
 5 20 50 30 
Gradient 24 
Time 
(min) 
MetOH (%) 
0.1% 
FA 
ACN (%) 
Flow rate 250 μL min.1 0 50 10 40 
Column temperature : 30 ºC 0,5 20 50 30 
 1 40 50 10 
 4 50 10 40 
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 5 50 10 40 
Gradient 24 
Time 
(min) 
ACN (%) 0.1% FA (%) 
Flow rate 250 μL min.1 0 20 80 
Column temperature : 30 ºC 1,5 50 50 
 2,5 70 30 
 4 20 80 
 5 20 80 
Gradient 25 
Time 
(min) 
ACN (%) 0.01% FA (%) 
Flow rate 200 μL min.1 0 80 20 
Column temperature : 30 ºC 0.2 90 10 
 0.5 30 70 
 1 15 85 
 5 80 20 
Gradient 26 
Time 
(min) 
ACN (%) 0.01% FA (%) 
Flow rate 200 μL min.1 0 95 5 
Column temperature : 30 ºC 0.5 100 0 
 1 100 0 
 2 95 5 
 3 95 5 
 4 80 20 
 5 95 5 
  
6.2. Annex II : Form of Hcys and vitamins B  at pH 2- 8 
All images were adapted from chemicalize.org 
Hcys  
 
 
 
 
 
 
 
 
  
Pka values of Hcys 
Predominant forms of Hcys within the pH range of the column 
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Vitamin B6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PKA values of Vitamin B6 
 
 Predominant forms of Vitamin B6 within the pH range of the column 
Vitamin B9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PKA values of Vitamin B9 
 
Predominant forms of Vitamin B9 within the pH range of the column 
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Vitamin B12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PKA values of Vitamin B12 
Predominant forms of Vitamin B12 within the pH range of the column 
6.3. Annex III : MEPS procedures performed to extract efficiency 
Hcys 
 
MEPS procedure 1 
Cartridge condition 
250 μL of MetOH 
250 μL of 0.01%FA 
Sample loading 
5 x 50 μL of standard containing Hcys and 25 μL of 
TCEP (390 mmol/L) 
Sorbent washing 1 x 50 μL 0.01% FA 
Elution 3 x 30 μL 20% MetOH 
MEPS procedure 2 
Cartridge condition 
100 μL of MetOH 
100 μL of H20 
Sample loading 
100 μL of standard containing Hcys and 10 μL of 
TCEP (390 mmol/L) 
Sorbent washing 100 μL of H20 
Elution 
100 μL of % MetOH 
A: 20% 
B: 40% 
C:80% 
MEPS procedure 3 
Cartridge condition 
100 μL of MetOH 
100 μL of 0.01% FA 
Sample loading 
2 x100 μL of standard containing Hcys and 20 μL of 
TCEP (390 mmol/L) 
Sorbent washing 100 μL of 0.01% FA 
Elution 50 μL of MetOH 
MEPS procedure 4 
Cartridge condition 100 μL of MetOH 
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100 μL of Sodium Acetate 100 mmol/L 
Sample loading 
100 μL standard containing Hcys and 20 μL of TCEP 
(390 mmol/L) prepared in Sodium acetate 100 mmol/L 
Sorbent washing 
100 μL of Sodium Acetate 100 mmol/L 
100μL of MetOH 
Drying 5 min of cycles of aspiration of air 
Elution  50 μL of 5% Ammonium hydroxide/95% MetOH 
MEPS procedure 5 
Cartridge condition 
100 μL of MetOH 
100 μL of Ammonium Acetate 100 mmol/L 
Sample loading 
100 μL standard containing Hcys and 20 μL of TCEP 
(390 mmol/L) prepared in Ammonium acetate 100 
mmol/L 
Sorbent washing 
100 μL of Ammonium Acetate 100 mmol/L 
100μL of MetOH 
Elution 50 μL of 5% Ammonium hydroxide/95% MetOH 
MEPS procedure 6 
Cartridge condition 
250 μL of ACN 
250 μL of 0.01%F A 
Sample loading 
200 μL of Standards containing Hcys and 20 μL of 
TCEP (390 mmol/L) 
 
Sorbent washing 
250 μL0.01% FA 
 
Elution  80 μL ACN/0.01% FA 
 
